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ABSTRACT 
 
 
Arrhythmias are often caused by aberrant ion channel activity, resulting in 
remodeling of the cardiac action potential.  Two K+ currents, IKs and IKr, contribute 
to phase III repolarization of the human cardiac action potential. Human ether-a-
go-go-related gene 1 (hERG1), a voltage-gated potassium channel, underlies IKr.  
Alterations in the repolarization phase of the action potential, and in particular IKr, 
can lead to arrhythmias, long or short QT syndrome, heart disease, and sudden 
cardiac death.  HERG1A has two putative N-glycosylation sites located in the S5-
S6 linker region, one of which is N-glycosylated.  The aim of the first study was to 
determine whether and how N-linked glycosylation modifies hERG1A channel 
function.  Voltage-dependent gating and kinetics of hERG1A were evaluated 
under conditions of full glycosylation, no sialylation, in the absence of complex N-
glycans, and following the removal of the full N-glycosylation structure.  The 
hERG1A steady state activation relationship was shifted linearly along the 
voltage axis by a depolarizing ~9 mV under each condition of reduced 
glycosylation.  Steady state channel availability curves were shifted by a much 
greater depolarizing 20–30 mV under conditions of reduced glycosylation.  There 
was no significant difference in steady state gating parameters among the less 
glycosylated channels, suggesting that channel sialic acids are responsible for 
ix 
most of the effect of N-glycans on hERG1A gating.  A large rightward shift in 
hERG1A window current for the less glycosylated channels was caused by the 
observed depolarizing shifts in steady state activation and inactivation.  The 
much larger shift in inactivation compared to activation leads to an increase in 
hERG1A window current.  Together, these data suggest that there is an increase 
in the persistent hERG current that occurs at more depolarized potentials under 
conditions of reduced glycosylation.  This would lead to increased hERG1A 
activity during the AP, effectively increasing the rate of repolarization, and 
reducing AP duration, as observed through in silico modeling of the ventricular 
AP.  The data describe a novel mechanism by which hERG1A activity is 
modulated by physiological and pathological changes in hERG1A glycosylation, 
with increased channel sialylation causing a loss of hERG1A activity that would 
likely cause an extension of the ventricular AP.  The second study was to 
evaluate possible changes in antibiotic drug block as a result of alterations to N-
glycosylation.  We determined that N-glycans play a protective role on the 
hERG1A channel.  SMX, Erythromycin, and Penicillin G were assessed 
individually at three concentrations.  The data showed increases in antibiotic 
block with decreases in N-glycans.  In addition, alterations in the voltage-
dependence of block with changes in N-glycans were observed.  SMX block was 
voltage-independent at each drug concentration under conditions of reduced 
sialylation only.  Overall, these data indicate a functional role for N-glycosylation 
in the modulation of hERG1A antibiotic block, suggesting that even small 
changes in channel N-glycosylation modulate hERG1A block, and thereby likely 
x 
impact the rate of action potential repolarization.  The data from these studies 
enhances our understanding of the role of N-glycosylation on hERG1A function 
and drug block, and how that role will impact the cardiac action potential and 
overall cardiac excitability. 
1 
 
 
 
 
CHAPTER 1 
INTRODUCTION 
Normal heart function 
The heart is a muscular organ that is responsible for pumping blood throughout 
the body by repeated, rhythmic contractions.  It is made up of cardiac muscle 
which is found only within this organ.  The average human heart beats about 72 
times per minute.  The right side of the heart collects the de-oxygenated blood 
from the body into the right atrium and then pumps it via the right ventricle into 
the lungs for gas exchange.  Then the left atrium fills with oxygenated blood 
before moving to the left ventricle which pumps it out to the body.  The ventricles 
are thicker and stronger than the atria. The muscle wall surrounding the left 
ventricle is thicker than the wall surrounding the right ventricle due to the force 
needed to pump the blood through the body. 
 
The heart is effectively a syncytium, a meshwork of cardiac muscle cells 
interconnected by contiguous cytoplasmic bridges1-3.  These muscle cells linked 
together communicate when to contract and relax the heart through the pathway 
of conduction.  Conduction is the electrical signaling pathway through the heart 
that produces normal cardiac rhythm (see Figure 1).  This pathway is comprised  
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Figure 1. Normal electrical conduction through the heart. Conduction in the heart 
begins with the sinoatrial (SA) node generating the electric signals that will 
spread to the atrioventricular (AV) node resulting in ventricular depolarization 
followed by repolarization in the reverse direction.   
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of five elements: sino-atrial (SA) node, atrio-ventricular (AV) node, bundle of His, 
left and right bundle branches, and Purkinje fibers.  The SA node is the natural 
pacemaker of the heart.  It releases electrical stimuli at a regular rate that is 
dictated by the needs of the body.  Each stimulus passes through the myocardial 
cells of the atria creating a wave of contraction which spreads rapidly through 
both atria.  This stimulus from the SA node reaches the AV node and is delayed 
briefly so that the contracting atria have enough time to pump all the blood into 
the ventricles. Once the atria are empty of blood the valves between the atria and 
ventricles close.  The electrical stimulus passes through the AV node and Bundle 
of His into the Bundle branches and Purkinje fibers.  This allows all the cells in 
the ventricles to receive an electrical stimulus causing them to contract 
(depolarize).  Once the ventricles have contracted, the cells then relax, 
repolarize, and are then ready for the next stimulus.  Figure 2 displays an 
electrocardiogram (ECG) that is a recording a heart rhythm. 
 
The electrical stimulation moving through the heart is propagated by action 
potentials.  The action potential (AP) is the hallmark of electrical communication 
used by the body and is the rapid transient depolarization and subsequent 
repolarization produced by a concerted effort of many different ion channels (see 
Figure 3).  There are two types of APs in the heart: fast and slow.  The slow 
action potential consists of phases 0, 3, and 4, whereas the fast action potential 
has phases 0, 1, 2, 3, and 4.  In phase 0 of the fast AP, voltage-gated (Nav) 
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Figure 2. Normal ECG.  An ECG is a recording of conduction across the chest. A 
normal ECG illustrates that the heart is working correctly and allows for detection 
of changes in how the heart beats. Figure adapted from 
eleceng.dit.ie/tburke/biomed/ecg.png. 
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Figure 3: Action potential waveforms in the heart. The top panel illustrates 
examples of the variety of AP waveforms found in the heart. The different 
currents involved in the fast AP are shown in the lower pane. Figure modified 
from cvphysiology.com. 
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channels open and cause the rapid depolarization of the membrane, due to 
sodium (Na+) ions moving into the cell down their electrochemical gradient.  Nav 
channels then inactivate quickly while voltage-gated potassium (Kv) channels 
activate to produce a transient outward current (Ito).  This results in the small, 
rapid repolarization seen in phase 1.  The plateau phase (phase 2) consists of  
voltage-gated calcium (Cav) channels activating  producing an inward current that 
is compensated with an outward potassium (K+) current (IKur).  In phase 3, the 
outward K+ current, IKr and IKs, starts to exceed the inward calcium current, 
thereby repolarizing the cell back to its resting membrane potential.  The diastolic 
potential (phase 4) is accomplished by an outward K+ current equaling the action 
of the Na+/K+-ATPase pump. 
 
Normal heart rhythm occurs when the cardiac muscle cells, the conduction 
pathway, and the voltage-gated ion channels all work properly and in sync with 
one another.  Any disruption can potentially cause dysfunction of the heart. 
 
Arrhythmias and conduction dysfunction 
Cardiac arrhythmias are considered a large collection of conditions where there 
is abnormal electrical activity in the heart4,5.  The heart may beat too fast or too 
slow, and can be regular or irregular.  Many arrhythmias are life-threatening and 
can result in cardiac death2,6.  Other arrhythmias may be less threatening and 
symptoms may not present, but it may predispose an individual toward a stroke 
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or embolus.  There are many types of arrhythmias from bradycardias, 
tachycardias, automaticity, reentrant, and fibrillations (see Figure 4)7.  
Bradycardia is a slowing of the heart beat that may be brought on by a slowed 
signal from the SA node, a loss of activity from the SA node, or by blocking the 
electrical signal from the atria to the ventricles (AV block).  Tachycardia is an 
increase in heart rate about 100 beats per minute.  Tachycardia is not always 
considered an arrhythmia.  The sympathetic nervous system acts on the SA 
node to increase heart rate in times of exercise or emotional stress.  When 
tachycardia results from extra abnormal impulses in the cardiac cycle, then it is 
considered to be pro-arrhythmic.  Automaticity refers to the potential a cardiac 
muscle cell firing an action potential.  All cardiac muscle cells have the ability to 
initiate an AP, but normal conduction keeps the generation of APs to designated 
cells, such as the SA node.  When a cardiac muscle cell initiates an AP, it is 
commonly called an ectopic focus.  This has the potential of causing an extra 
beat or seriously altering the contraction and proper flow of blood throughout the 
body.  An ectopic focus has the possibility of permanently modifying the 
efficiency of the heart to pump blood.  Reentrant, or re-entry, arrhythmias occur 
when the electrical signal gets stuck in a small part of the heart and travels back 
and forth in that area.  The normal signaling pathway occurs through the whole 
heart.  This dysfunction may occur when a signal is delayed traveling to an area 
in the heart. The heart cells have the potential of treating the delayed signal as a 
new signal and will propagate this “new” signal while the old, or original, signal is  
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Figure 4: Dysfunctions in the heart. Alterations in ion channel activity can cause 
multiple cardiac dysfunctions including Long QT syndrome, torsades de pointes, 
and ventricular fibrillation. Figure modified from Keating 20017. 
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still moving through the rest of the cardiac heart cells.  This may lead to atrial 
flutter and ventricular tachycardia.  Fibrillation builds on the reentrant 
phenomenon where the electrical impulse is stuck and in one area, except it is 
now stuck in an entire chamber of the heart, i.e. atria or ventricle.  The chamber 
essentially flutters from the chaos of multiple signaling moving in every direction.  
Although atrial fibrillation is not always considered life-threatening, ventricle 
fibrillation (VF) is a medical emergency.  VF is considered cardiac arrest since 
the heart cannot pump blood when the ventricle cannot contract.  This can lead 
to death in a matter of minutes.  Sudden Arrhythmia Death Syndrome (SADS) is 
the term used to describe death in a person due to an arrhythmia.  The most 
common form of this is coronary artery disease that kills over 300,000 people 
every year in the US. 
 
Long QT, Short QT, Brugada’s 
Disruption of the conduction in the heart can occur as a result of many reasons 
from diseases (such as heart disease and diabetes), aging, smoking, excessive 
drinking, inherited abnormalities, and alterations in cardiomyocyte action 
potentials.  
 
Cardiac action potential maladies can be caused by alterations in ion channel 
function.  Figure 4 displays one of these dysfunctions, Long QT Syndrome 
(LQTS).  LQTS is an extension of the QT segment as seen on an 
10 
 
electrocardiogram (ECG).  The QT segment involves the depolarization and 
subsequent repolarization of the ventricles in the heart.  The QRS segment 
shows the depolarization of the ventricle and the T segment illustrates the 
repolarization of the ventricle.  LQTS can be either inherited or acquired.  
Acquired LQTS typically happens as a result of medications that alter ion channel 
function.  Inherited LQTS occurs when there is a mutation of a gene8-16.  
Currently, there are twelve known inherited LQTS categories with LQT1, LQT2, 
and LQT3 being the most common (see Figure 5).  LQT1 and LQT2 make up 
about 65% of all LQTS cases.  LQT1 involves mutations the the KvLQT1 
channel.  KvLQT1 encodes IKs, one of two major repolarizing currents of the AP.  
These mutations will delay repolarization of the action potential and increase 
action potential duration (APD) leading to elongation of the QT segment.   
Although LQT1 is the most common form of LQTS, it is the least severe.  LQT2 
occurs as a result of mutations in the hERG1 channel.  HERG1 underlies IKr, the 
other major repolarizing current of the cardiac AP.  Altering the repolarization 
phase, essentially delaying it, will extend the action potential and lengthen the 
QT segment.  IKr is the current responsible for ending the AP and normal function 
of hERG1 could be considered protective against early after depolarizations 
(EADs).  LQT3 entails mutations in SCN5A, the channel that underlies the main 
sodium current in phase 0 of the action potential.  Extension of the depolarization 
phase of the AP through mutations that cause a decrease in inactivation of the 
Nav channel will also elongate the QT segment.  Again, this has the potential of  
11 
 
 
 
 
Figure 5. Long QT disorder list.  A list of known LQT disorders and the genes 
associated with each disorder. Figure from eplabdigest.com. 
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causing disruption to normal heart rhythm.  Interestingly, Brugada Syndrome can 
also be caused by mutations in SCN5A9.  These mutations in SCN5A, that 
underlies INa, cause a loss-of-function resulting in elevation of the ST segment 
and dispersion of repolarization.  This will cause a phase 2 reentry that has the 
potential to trigger ventricular tachycardia.  In addition to LQTS, another disease 
that involves the QT segment is called Short QT Syndrome (SQTS).  SQTS is the 
result of a shortening of the QT segment typically resulting from an increase in 
potassium current.  The main repolarizing potassium currents are IKs and IKr
17-19.  
Increases in these currents can be the consequence of mutations of the channels 
that underlie each current.  Whether the QT segment is lengthened or shortened, 
the result can be the same.  Any alteration to the QT segment can alter the 
cardiac AP and can lead to cardiac dysfunction15,16,18-20.  
 
Alterations in IKr can cause arrhythmias 
Alterations in IKr can lead to cardiac dysfunction
8,11,15,18,20-26.  If the current is 
blocked, then an extension of the QT segment occurs and can result in LQT2.  If 
there is an increase in IKr, then a shortening of the QT segment transpires and 
this may still lead to an arrhythmic event27. 
 
HERG1A underlies IKr 
Human ether-a-go-go-related gene 1 (hERG1) is the voltage-gated potassium 
channel that underlies IKr
19,28-31.  IKr is one of two major potassium currents that 
13 
 
help repolarize the cardiac ventricular action potential (see Figure 6).  Phase 3 is 
considered the “rapid repolarization” phase where IKr is contributing nearly all of 
the K+ efflux from the cell.  This removal of potassium causes a rapid change in 
the membrane potential from positive to negative potentials. 
 
HERG1A activity during the ventricular AP 
HERG1A has a unique functionality when it comes to the cardiac action 
potential19,28-31.  When the AP begins at phase 0, the membrane potential moves 
very quickly from negative to positive potentials.  Phase 0 happens in ~10 ms. 
HERG1A is starting to transition from closed to open.  However, hERG1A’s 
inactivation rate is faster than its activation rate at positive potentials.  By the time 
phase 0 is complete and the membrane potential is around +40 mV, hERG1A 
channels have mostly transitioned to the inactivated state.  This allows for 
hERG1A to be prepared for the final part of the plateau phase and the 
repolarization phase.  As the membrane potential starts to fall from positive 
potentials, hERG1A transitions for inactive to the open state, starting the flow of 
K+ efflux from the cell.  As the potential becomes even more negative with K+ 
efflux, hERG1A channels recover even faster to their open state.  This could be 
considered a positive loop feedback.  This large efflux of potassium from the cell 
can be seen as the steep slope of phase 3 of the AP.  Once the membrane 
potential nears the resting potential, the channels transition to their closed state, 
ready to start the next action potential. 
14 
 
 
 
 
Figure 6: HERG1A activity in the heart. HERG1A is in an inactivated state for 
most of phase 0 and 1.  During phase 2 repolarization, hERG1A transitions back 
into its open state allowing a large efflux of potassium (phase 2 and 3). Figure 
from Keating 20017. 
 
 
 
 
 
 
 
 
 
 
15 
 
HERG1A characteristics 
HERG1A is a voltage-gated potassium channel18,31.  It consists of four subunits 
coming together to create a pore-forming channel.  Each subunit consists of six 
trans-membrane domains or segments (S1-6) (see Figure 7).  Segments 1-4 are 
called the voltage-sensing domains with segment 4 (S4) having positive charges 
every three amino acids.  These charges sense a change in the membrane 
potential and will move through the membrane outward allowing the channel to 
open.  Segments 5 and 6 are the pore-forming domains.  The linker region that 
connects segments 5 and 6 is called the pore-forming loop, or P-loop, and 
shapes the pore region of the channel.  Within the P-loop is a recognized amino 
acid sequence that determines if it is a K+ channel.  This sequence is GYG  
(glycine - tyrosine - glycine).  This sequence is thought to allow the K+ channel to 
be selective towards K+ ions32.  However, there are exceptions to this and 
hERG1A is one of them.  HERG1A’s sequence is GFG (glycine - phenylalaline - 
glycine), but is still selective for K+ ions.  Once hERG1A has four subunits 
together to form a functional channel, it can then start to allow K+ ions to flow 
through the pore region.  This occurs by the channel transitioning from the closed 
state to an open state.  When the S4 segment senses a change in the membrane 
potential, the segments (there is one on each subunit or four total) will move 
outward causing a conformational change in the channel, opening the pore 
region.  K+ ions will start to flow out of the cell.  Figure 8 shows typical gating 
properties of hERG1A.  In addition to opening and closing, hERG1A can also 
16 
 
 
 
 
Figure 7: HERG1A channel. The hERG1A channel consists of four subunits (one 
is pictured).  The red arrows point to the N-glycosylation consensus sequences 
found on the P loop of hERG1A. Only the site N-terminal to the pore is 
glycosylated.  Figure from Sanguinetti 200631. 
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Figure 8: Gating properties of hERG1A.  The above panel displays the unique 
gating properties of hERG1A.  Note that the rate of inactivation is faster as the 
membrane potential becomes more positive, essentially transitioning past the 
open state. At positive potentials, there is a decrease in hERG1A current 
because most channels are in the inactivated state33. 
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inactivate, but only through C-type inactivation.  Channel inactivation can happen 
one of two ways; C-type or N-type.  N-type inactivation is also called the ball-and-
chain method where the N-terminus moves up and occludes the pore region to 
stop the flow of ions.  C-type inactivation is different.  C-type inactivation happens 
by a constricting of the pore-loop area of the channel, squeezing shut and thus 
stopping the flow of ions.  Most C-type inactivation is slow and doesn’t always 
completely inactivate.  However, C-type inactivation for hERG1A is fast and at 
very positive potentials allows almost no potassium efflux31. 
 
The hERG1A channel has been implicated in both inherited and drug-induced 
arrhythmias4,7,14,19,22,23,27,28,34-58.  Mutations are associated with ventricular 
fibrillation, torsades de pointes (TdP), and arrhythmias.  Drug-induced 
arrhythmias can be triggered by occlusion of the pore region by certain drugs, 
and/or by alterations in function of the channel by a mutation in hERG1A. 
 
Over two hundred hERG1A mutations have been characterized that cause 
disruption (reduction) of IKr and potentially cause long QT syndrome 
(LQTS)8,11,15,18,20-26.  The resulting LQTS can be caused through multiple 
hERG1A dysfunctions.  For example, mutations can lead to misfolding of the 
protein causing retention in the endoplasmic reticulum (ER) where rapid 
degradation will occur.  Secondly, the mutation can produce dominant-negative 
suppression or alter gating of the channel when there is co-assembly of mutant 
19 
 
and wild-type subunits.  In either case, a loss-of-function occurs and a reduction 
in IKr initiates the prolongation of phase II and III and an extension of the cardiac 
action potential.  The extension of the action potential can lead to early after 
depolarizations (EADs) and arrhythmias.  There is one known mutation in the 
hERG1A channel that causes a shortening of the QT interval27.  The shortening 
is due to a gain-of-function by abolishment of inactivation.  The repolarization 
phase of the AP is more rapid and ventricular fibrillation and arrhythmias can 
result from this “short QT syndrome”.  
 
HERG1A is unique among voltage-gated potassium channels in that it can be 
inhibited by many different types of drugs.  HERG1A can be blocked by drugs 
including antibiotics, antihistamines, antiarrhythmics, antipsychotics, and 
antimicrobials, directly leading to induced arrhythmias.  Because of the diversity 
in structures among these drugs, establishing how and where hERG1A is 
blocked has proven difficult.  Drug-induced arrhythmias are widespread and 
affect individuals of all age groups.  Because prolonging the QT interval can lead 
to TdP, arrhythmias, and even death, pharmaceutical companies screen all 
potential drug candidates for hERG1A channel inhibition. 
 
HERG1A N-glycosylation 
HERG1A has two extracellular, N-linked glycosylation consensus sites located in 
the S5-S6 linker region of the channel, very near the pore and selectivity filter. 
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The consensus sequence consists of NXS/T with N being Asparagine, X being 
any amino acid except Proline, and S/T being a Serine or Threonine.  Through 
work completed by others and confirmed by our lab, the N-linked glycosylation 
site at N629 is not glycosylated44,59,60.  It is thought that the N629 site is too close 
to the S6 segment and is not exposed to the glycosylation machinery to have 
glycans attached.  Thus, the functional hERG1A tetramer has the capacity for 
four N-glycosylation structures to be attached within the pore region. 
 
Known role of glycosylation on hERG1A 
Most research completed about the glycosylation of hERG1A has focused mainly 
on trafficking concerns for the channel.  Originally, it was thought that N-linked 
glycosylation was needed for proper trafficking of hERG1A to the surface of the 
cell.  A repeat of the study by Zhou showed that N-glycosylation is not needed for 
correct trafficking to the surface, but removal of N-glycosylation altered the 
stability of the channel in the membrane over the course of twenty four 
hours8,44,59,60.   
 
Glycosylation effects on other channels 
Many voltage-gated ion channels are heavily glycosylated.  All Nav and many Kv 
channels are glycosylated, although in different locations on the channel and with 
differing amounts and types of glycans.  Several studies have suggested that 
glycosylation, in particular, sialylation, may impact channel function61-72.  Gating 
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of Nav1.4, Kv1.1, Kv1.2, and the Drosophila ShB channels are shifted to more 
depolarized potentials with a reduction in N-glycosylation.  In addition, data 
suggest that rat neonatal and adult atrial and adult ventricular Nav channels are 
more sialylated and therefore are more affected by changes in sialylation that 
neonatal ventricular Nav channels.   
 
Glycosylation pathway 
Glycosylation is a post-translational modification.  Glycosylation structures 
attached to ion channels can make up more than 30% of a mature protein’s 
mass.  The addition and removal of glycans from proteins is completed by 
glycosidases, glycosyltransferases, and transport proteins (see Figure 9).  The 
Consortium for Functional Glycomics recognizes more than 500 human genes 
involved in glycosylation.  With the human genome being composed of 
approximately 30,000 genes, the genes required for the addition and removal of 
glycans make up more than 1% of the entire genome66.  Two forms of 
glycosylation have been identified: N-linked and O-linked glycosylation.  The 
addition of glycosylation is not template-driven, but it is a highly ordered 
process73,74.  Each step in the pathway determines the next step. 
 
N-glycosylation begins in the endoplasmic reticulum (ER).  An oligosaccharide 
precursor, composed of two core N-acetylglucosamines (GlcNAc) and five 
mannose residues, is linked to a dolichol-phophate on the cytosolic side of the 
22 
 
 
 
 
Figure 9: Glycosylation pathway. N-glycosylation is a regulated pathway in which 
multiple proteins work collaboratively to add/remove sugars.  The top panel 
shows the initial steps in the pathway, and the bottom panel shows the complex 
glycosylation that occurs in the Golgi.  Figure from clemonslab.caltech.edu/n-
linked.html. 
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ER.  The lipid-linked precursor is then flipped across the bilayer into the lumen of 
the ER.  The precursor is complete with the addition of mannose and glucose 
structures.  A protein complex, named oligosaccharyltransferase (OST), transfers 
the dolichol precursor en bloc to an asparagine residue on a newly translated 
protein.  Following the covalent attachment of the precursor to the asparagines 
residue, glucosidases remove all of the glucose residues.  The glycoprotein 
(newly glycosylated protein) is translocated to the cis-Golgi where the mannoses 
are trimmed down leaving only three.  Formation of complex glycans takes place 
in the medial and trans-Golgi with sialic acid (SA) often being the terminal glycan 
structure.  Sialic acids are negatively charged at physiologic pH and can be 
attached to other sialic acids.  These sialic acids have the potential of 
contributing to the negative surface charge of the protein. 
 
Congenital disorders of glycosylation (CDG) 
Currently, there are twenty-six forms of congenital disorders of glycosylation 
(CDG) characterized75-78.  Of these twenty-six forms, sixteen affect N-linked 
glycosylation.  CDG is a genetic disorder caused by glycosylation genes that are 
missing or mutated.  These defects can alter multiple steps in the glycosylation 
pathway.  CDG produces glycoproteins with decreased amounts and types of 
glycans.  Multiple systems within the body are influenced by CDG including 
cardiovascular, muscular, and neuronal. 
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Chagas’ disease  
Chagas’ disease, also known as American trypanosomiasis, is a human parasite 
disease that has no vaccine and no known cure79-83.  The parasite, named 
Trypanosoma cruzi, infects its host and releases a trans-sialidase to assist the 
transfer of sialic acid residues from the host to the parasite.  The host tissue 
typically is the human heart, specifically cardiomyocytes.  Sialic acid is a terminal 
residue located on glycosylation structures.  Many ion channels could be affected 
by this alteration in glycosylation.  Symptoms from this disease include 
arrhythmias, myocarditis, cardiomyopathy, cardiac failure, and death. 
 
Glycosylation is differentially expressed and remodeled in the heart 
Cardiac glycogene expression is highly regulated66.  This was determined by 
measuring the relative expression of hundreds of glycogenes using GeneChip 
microarray analysis of mRNA isolated from neonatal and adult atria and 
ventricles.  Microarray data were validated using real-time RT-PCR (qPCR) 
analysis.  The microarray and qPCR data were consistent.  The data showed that 
almost 50% of glycogenes tested were significantly differentially expressed 
among the four myocyte types studied.  Additionally, glycogene expression 
between atria and ventricles at a single developmental stage and throughout 
development of each chamber was also highly regulated.  The result of the 
removal of just one glycogene was enough to alter the conductance-voltage 
relationship for Nav gating in atrial myocytes in mice. 
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Subunit vs cell specific effects of glycosylation 
N-glycosylation can affect cardiac action potential waveforms in one of two ways: 
subunit or cell-specific.  Altering N-glycosylation on a specific channel can modify 
the AP.  Furthermore, modulating the glycosylation machinery available in a 
tissue can change the N-glycosylation of all channels in the tissue and still have 
an effect on the AP. 
 
Summary 
It is well accepted that alterations to IKr that affect the action potential waveform 
can lead to arrhythmias.  Our previous work with sodium and potassium channels 
showed that a change in sialylation modulates gating.  In addition, certain 
disorders, CDG and Chagas’ disease, display symptoms of cardiac unrest with a 
change in glycosylation.  The hERG1A channel is heavily glycosylated and 
studies have shown glycosylation of hERG1A may be needed for proper stability 
in the membrane.  However, very little has been done to determine a specific role 
or mechanism for N-glycans in hERG1A activity.  Here, we describe in detail, a 
role for N-glycans on hERG1A gating and kinetics.  We find that N-glycans limit 
hERG1A activity, thereby causing an extension of the cardiac AP. 
 
In addition, we questioned the probable modulation, by N-glycosylation, of drug 
inhibition of three well-prescribed antibiotics, Sulfamethoxazole (SMX), 
Erythromycin, and Penicillin G.  This study will provide insight into understanding 
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the potential role of glycosylation for inherited, drug induced, and potentially 
disease induced (eg. Chagas’ disease) arrhythmias.  With arrhythmias claiming 
the lives of hundreds of thousands of people every year and with millions of 
people living with life-threatening arrhythmias daily, a greater awareness is 
needed. 
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CHAPTER 2 
MATERIALS AND METHODS 
Chinese hamster ovary cell culture and transfection 
Pro5, Lec2, and Lec1 cells were grown in minimal media and transfected with 
channel cDNA as previously described84,85.  The cells were plated at ~50% 
confluence onto 35 mm dishes 24 hours prior to transfection with a solution of 1 
mL Opti-MEM (Invitrogen), 8 µL lipofectamine (Invitrogen), and 2.5 µg of channel 
cDNA and incubated at 37 C in a 5% CO2 humidified incubator.  24 hours post-
transfection, the transfection media was replaced with growth media, consisting 
of alpha-minimum essential medium (αMEM; Invitrogen) with (Pro5 and Lec1) 
and without (Lec2) ribo- and deoxyribonucleosides supplemented with 10% fetal 
bovine serum (FBS; Hyclone), 100 U/mL penicillin, and 100 µg/mL streptomycin 
(Mediatech).  Cells were incubated at 37 C for another 48 hours prior to 
electrophysiological recordings. 
 
Vector construction and mutagenesis 
The hERG1A cDNA in a pcDNA3 vector was a gift from Gail A. Robertson 
(University of Wisconsin).  Vector construction and mutagenesis were performed 
similar to that previously described.  The cDNA containing hERG1A open reading 
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frame was inserted into either a pIRES2-DsRED2 vector or a pIRES2-EGFP 
vector.  The IRES2 vectors contain an internal ribosome entry site that allow both 
the gene of interest and the DsRED2 or EGFP gene to be translated from a 
single biscistronic mRNA. 
 
Electrophysiology and data analysis 
Whole cell recordings in CHO cells 
The Pro5/Lec2/Lec1 expression system, cell lines of Chinese Hamster Ovary 
cells, has been used successfully to determine the effects of glycosylation on 
channel gating.  The Pro5 cell line produces normal N-glycosylation and is the 
parental cell line for both Lec2 and Lec1.  The Lec2 cell line is deficient in the 
CMP-sialic acid transporter and produces essentially non-sialylated proteins. 
This cell line serves as a model for CDG type-IIf.  The Lec1 cell line produces 
proteins in a mannose-rich, or core N-glycosylated, state because of a deficiency 
in the GlcNAc-T1 (N-acetylglucosaminyltransferase I) causing a disruption in 
complex glycans being added to glycoproteins85. 
 
Whole cell current recordings were performed using pulse protocols, solutions, 
whole cell patch clamp techniques, and data analyses as previously described. 
An Axon 200B patch-clamp amplifier in combination with a CV203BU headstage 
(Axon Instruments) and a Nikon TE200 inverted microscope were used.  Pulse 
acquisition software (HEKA) operating on a Pentium III computer (Dell 
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Computers) was utilized for pulse protocol generation.  The ensuing analog 
signals were digitized using an ITC-16 AD/DA converter (Instrutech).  All 
experiments were conducted at room temperature (~22 C). Drummond capillary 
tubes were pulled into electrodes with a resistance of 1-2 M  using a model P-97 
Sutter electrode puller.  Series resistance was compensated 95-98%.  The 
extracellular solution was (mM): 65 NaCl, 5 KCl, 1MgCl2, 2 CaCl2, 155 sucrose, 5 
glucose, 10 Hepes (pH 7.3).  The intracellular solution used was (mM): 70 KCl, 
65 KF, 5 NaCl, 1MgCl2, 10 EGTA, 5 glucose, 10 Hepes (pH 7.3).  For the drug-
perfusion studies, the extracellular solution was identical to that listed above plus 
the addition of each concentration of drug listed in Table 1.  Immediately prior to 
use, all solutions were filtered with a 0.2 µm Gelman filter.  To ensure complete 
dialysis of the intracellular solution, data was collected at least 5 minutes after 
attaining whole cell configuration. 
 
Conductance-voltage relationship for CHO cell recordings 
Steady-state and kinetic gating parameters were examined through the use of 
standard pulse protocols and solutions described by our lab and others.  Cells 
were held at -80 mV, stepped to more depolarized potentials (-80 mV to +50 mV 
in 10 mV increments) for 4 seconds, then stepped back to -50 mV for another 4 
seconds, and returned to the holding potential.  Steady-state whole cell 
conductance values (G) were determined by measuring the peak current (I) of 
the tail current elicited at each test potential (Vp) and predicting a K
+ Nernst 
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Table 1. Concentrations for antibiotic drug study 
 
Drug Name Low 
Concentration 
Mid 
Concentration 
High 
Concentration 
Erythromycin 25 µg/mL 100 µg/mL 200 µg/mL 
Penicillin G 10 µg/mL 50 µg/mL 200 µg/mL 
Sulfamethaxozole 50 µg/mL 300 µg/mL 600 µg/mL 
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equilibrium potential (Ek = -84 mV) using Ohm’s law (G = I/(Vp - Ek)).  The 
maximum conductance generated by each cell was used to normalize the data 
for each cell to its maximum conductance by fitting the data to a single 
Boltzmann distribution (equation 1, solving for maximal conductance).  These 
single Boltzmann distributions were used to determine the average Va ± SEM and 
Ka ± SEM values.  The normalized data were averaged with those from the other 
cells and the resulting average G-V curve was fit via least squares using the 
Boltzmann relation below:  
Fraction of maximal conductance = [1 + exp-((V-Va)/Ka)]
-1                   equation (1) 
where V is the membrane potential, Va is the voltage of half-activation, and Ka is 
the slope factor. 
 
Steady-state inactivation 
Cells were held at -80 mV before stepping to +20 mV for 3 seconds.  Then we 
stepped to -120 mV to +60 mV (in 10 mV increments) for 30 ms before stepping 
back to +20 mV for 1 second and then returned to the resting potential.  The 
maximum current generated by each cell was used to normalize the data for 
each cell to its maximum current by fitting the data to a single Boltzmann 
distribution (equation 2, solving for maximal current), from which the mean Vi ± 
SEM and Ki ± SEM values were determined. 
Fraction of maximal current = yo + [1 + exp-((V-Vi)/Ki)]
-1                      equation (2) 
where V is the membrane potential, Vi is the voltage of half-inactivation, Ki is the 
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slope factor, and yo is the fraction of current that comes from constitutively active 
channels. 
 
Window Current 
The product of the two Boltzmann distributions for steady-state activation and 
inactivation. See formulas above. 
 
Time constants for deactivation (Tn) 
The deactivation protocol was set up to start at the membrane potential of -80 
mV and then step to +20 mV for 1.6 seconds before stepping from -40 mV to -
100 mV (in 10 mV increments) for 6 seconds each and then returning to the 
resting potential.  Deactivation time constants were determined by fitting the 
current trace described above for each voltage tested.  Whole current traces 
were fitted using the Hodgkin-Huxley function of the PulseFit software suite 
(HEKA).  The current trace data were fitted to an exponential function. 
 
Computer simulation of action potential 
The Tentusscher-Noble-Noble-Panfilov model of human Endocardial ventricular 
myocyte was implemented to simulate the AP under four experimental 
conditions, namely Full glycosylation, Reduced sialylation, N-Glycanase treated, 
and Mannose-Rich1.  The extracellular concentration of K+, Na+, and Ca2+ are 5 
mM, 140mM and 2mM respectively.  The initial values of intracellular 
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concentration of K+, Na+, and Ca2+ are 138.3 mM, 11.6 mM, and 0.0002 mM.  
The rapid delayed rectifier current IKr is described by the following equation, 
IKr GKr Ko /5.4xr1xr2(V EK ), where xr1 is an activation gate and xr2 is an 
inactivation gate.  √Ko/5.4 represents the Ko dependence of the current
1.  Based 
upon the Va, Ka, Vi, Ki statistics from our voltage clamp experiments under four 
HERG +/- sugars treatments, we computationally fit the model steady state 
activation and inactivation curves. 
 
Whole cell homogenization 
Cells were rinsed with cold PBS and incubated for 5 minutes in ice cold sodium 
pyrophosphate buffer with protease inhibitors (PI; 20 mmol/liter tetrasodium 
pyrophosphate, 20 mmol/liter Na2PO4, 1 mmol/liter MgCl2, 0.5 mmol/liter 
iodacetamide, 1.1 µmol/liter leupeptin, 0.7 µM pepstatin, 76.8 nM aprotinin). Cells 
were then homogenized using manual tissue grinders.  The homogenates were 
centrifuged for 10 minutes at 1000 x g in a Beckman bench-top centrifuge.  The 
supernatant was centrifuged in an Eppendorf ultracentrifuge for one hour at 
50,000 rpm after which, the pellet was resuspended in an appropriate volume of 
sodium pyrophosphate buffer containing PIs.  The lysates were then stored at -
80 C and protein levels were determined using the Pierce BCA Protein Assay kit 
and a Beckman DU 530 spectrophotometer. 
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Cell surface biotinylation 
Cell surface protein isolation (Pierce) was performed on hERG1A expressed in 
Pro5, Lec2, and Lec1 cell lines.  The cells were grown in T75 flasks until ~95% 
confluent and then biotinylated for 30 minutes at 4 C.  Then the reaction was 
quenched, the cells harvested and lysed.  Next, the biotinylated proteins were 
isolated with NeutrAvidin™ Resin, rinsed, and then eluted with SDS-PAGE buffer 
plus 50mM DTT.  The protein sample at the end of the reaction is then run on a 
SDS-PAGE gel (see below) and probed with hERG1A antibody to detect if the 
hERG1A channel is found of the surface of the cell. 
 
Immunoblots 
Immunoblot gel shift analysis was performed as previously described65,84,86,87. 
Cell homogenates (1-3 µg/lane) were combined with one volume of 2x sample 
buffer (12.5% upper Tris buffer, 10% glycerol, 5% 2-mercaptoethanol, and 3% 
sodium dodecyl sulfate) and denatured in boiling water for 3 minutes.  Samples 
were then run on 5-7.5% SDS-PAGE gel for 90-110 minutes at 75-110 mV and 
then transferred on nitrocellulose membranes using a semi-dry transfer cell 
(BioRad).  HERG1A was detected using a polyclonal primary antibody, HERG C-
20, raised in goat (Santa Cruz Biotechnology).  After incubation with primary 
antibody, the blot was treated with a Swine Anti-Goat conjugated to HRP 
(Southern Biotech), secondary antibody, and visualized using an enhanced 
chemiluminescence kit (Pierce).  Deglycosylation of homogenates was 
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performed through 2 hour treatments at 37 C with 5 mU of N-Glycanase /9 µg of 
protein (PROzyme). 
 
Data analysis and statistics 
Data and statistical analyses were performed using Pulse/PulseFit (HEKA), 
Sigma Plot (SSPS inc.), and Microsoft Excel. Student T-test, ANOVA, and Tukey 
test were performed on the data produced by the electrophysiology recordings. 
Significance was determined by p<0.05 where applicable. 
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CHAPTER 3 
N-GLYCANS LIMIT HERG1A ACTIVITY 
Human ether-a-go-go-related gene 1 (hERG1), is the pore forming subunit of the 
voltage-gated potassium channel whose activity is responsible for IKr, a key 
component of late phase II and phase III of the human ventricular cardiac action 
potential (AP) 17,18,88.  A change in IKr can alter the repolarization phase of the AP 
that can lead to modulated cardiac conduction.  This altered conduction would be 
reflected in an ECG by a change in the QT interval. HERG1 dysfunction is 
responsible for Long QT2 disorders and a Short QT disorder16,19,89.  Abnormal 
hERG1 activity can lead to arrhythmias, torsades de pointes, cardiac disease, 
and sudden cardiac death7,16,20,21. 
 
The cardiac ventricular AP is comprised of 5 phases3. The rising phase, or phase 
0, is produced by the rapid activation of voltage-gated Na+ channels that then 
inactivate, shutting down the rapid depolarization. During this phase, hERG1A 
channels are beginning to transition out of the closed state to either the open or 
inactivated states. Phase 1 begins with a sharp, brief repolarization that occurs 
due to a transient outward K+ current, Ito.  The plateau, or phase 2, is produced 
by combating K+ efflux and Ca++ influx such that the membrane potential remains 
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almost constant. During phase 2 depolarization, hERG1A channels start to 
recover from inactivation by transitioning to their open state. A positive feedback 
loop begins as K+ leaves the cell, which will further repolarize the membrane and 
lead to the opening of additional hERG1A channels that are recovering from 
inactivation, thereby further repolarizing the membrane. Evidence for this positive 
feedback mechanism is observed by the steep slope of Phase 3. Phase 4 is the 
final recovery to the resting membrane potential before another AP begins. 
 
HERG1A channels do not inactivate through fast N-type inactivation, but through 
C-type mechanisms90. Typically, C-type inactivation is thought to involve pore 
constriction and is slower than N-type inactivation. However, hERG1A 
inactivation is fast and voltage-dependent and recovery from inactivation typically 
occurs rapidly with the transition from the inactivated back into the open channel 
state. This leads to increases in the rate of AP repolarization. Thus, any change 
in hERG1A voltage-dependent gating and/or kinetics would lead to a change in 
channel activity during the AP, and likely alter the rate of AP repolarization. 
 
Ion channels are heavily glycosylated, with up to 30% of a mature protein’s mass 
comprised of glycan structures69,91-94.  Our lab and others describe how changes 
in glycosylation and sialylation can affect gating and kinetics of voltage-gated Na+ 
and K+ channels65,68-71,87,93-97.  The addition and removal of glycans from proteins 
is completed by the activity of >200 glycosidases, glycosyltransferases, and 
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transport proteins (glycogenes). In a recent report, we showed that the cardiac 
glycome, defined as the complete set of glycan structures produced in the heart, 
varies between atria and ventricles, and changes differentially during 
development of each cardiac chamber98.  Specifically, we showed that nearly half 
of the 239 glycogenes tested were significantly differentially expressed among 
neonatal and adult atrial and ventricular myocytes.  The N-glycan structures 
produced among cardiomyocyte types were markedly variable. We went on to 
show that the regulated expression of a single glycogene was sufficient to 
modulate AP waveforms and gating of less sialylated voltage-gated Na+ channels 
consistently. These data provide initial insight into the possibility of a newly 
described mechanism for controlling and modulating cardiac excitability through 
regulated changes in cardiac glycosylation. 
 
HERG1A has two extracellular, N-linked glycosylation consensus sites, N598 
and N629, which are located in the S5-S6 linker region of the channel (or the 
pore region) and very near the selectivity filter. Work done by others and 
confirmed by our lab, showed that the N629 glycosylation site is not 
glycosylated60.  It is believed to be too close to the S6 domain and therefore not 
exposed to glycosyltransferases as the newly synthesized channel moves 
through the endoplasmic reticulum and Golgi.  However, the N598 glycosylation 
site is glycosylated.  Here we question whether and how alterations in the types  
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and amounts of N-glycans attached to hERG1A can modify channel gating and 
kinetics. 
 
Results 
HERG1A is differently glycosylated 
We questioned the impact of four variable glycosylation patterns on hERG1A 
function.  The Pro5, or parental cell line, is essentially fully glycosylated85.  The 
Lec2 cell line is deficient in a CMP-sialic acid transporter and produces 
glycoproteins with essentially no sialic acid, and serves as a model for CDGIIf75-
77,85.  The Lec1 cell line is deficient in GlcNAc-T1 (N-
acetylglucosaminyltransferase I) causing a disruption in the complex N-glycans 
being added to glycoproteins85.  As a result, a mannose-rich glycosylation 
structure is produced.  Exemplary N-glycan structures that are putatively 
produced in each cell type are shown in Figure 10.  The fourth glycosylation 
pattern was achieved through enzymatic deglycosylation, using N-glycanase to 
cleave the full N-glycan structure at the Asparagine residue.  Our previous work 
and work done by Thornhill’s group validate the use of this cell system and 
enzymatic treatments to study channel function under variable levels of channel 
glycosylation65,70,71,87,94-96. 
 
To demonstrate that hERG1A is glycosylated differently and is expressed on the 
cell surface under each condition of glycosylation, we performed immunoblot  
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Figure 10. HERG1A is differently glycosylated.  A:  Immunoblot of hERG1a 
expressing Pro5 cell lysates ± N-Glycanase treatment.  Lane 1:  Untreated 
control.  Lane 2:  N-glycanase treated.  B:  Surface biotinylated lysates extracted 
from Pro5 (Lane 1), Lec2 (Lane 2), and Lec1 (Lane 3) cells expressing hERG1A. 
Typical predicted schematic structures of N-glycans produced in each cell line.  
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analysis.  As seen in Figure 10A, for hERG1A expressed in Pro5 cells, treatment 
with N-glycanase causes a reduction in predicted molecular weight (MW), and a 
less diffuse banding pattern, suggesting that N-glycanase completely removes 
the N-glycan structure.  Analysis of surface channel expression shows that 
altered glycosylation does not affect channel trafficking of hERG1A in any of the 
cell lines tested.  The shifts in MW between Pro5, Lec2, and Lec1 suggest that 
each cell line glycosylates hERG1A differently, and is expressed on the cell 
surface.  Further, note the heterogeneous banding pattern of the Pro5 and Lec2 
lysates, and the more homogeneous pattern of the Lec1 and N-glycanase-
treated lysates, indicating the variability of glycosylated hERG1A protein 
expressed on the cell surface. 
 
HERG1A function is modulated by N-glycans 
hERG1A expressed in each cell line and following N-glycanase treatment 
produced typical hERG1A currents as illustrated in Figure 11.  Variable 
glycosylation had no significant effect on the hERG1A current densities.  
However, note the distinct characteristics of the current traces among the 
differently N-glycosylated hERG1A channels.  As an example for each condition 
of reduced glycosylation, note the larger and faster (deactivating) tail currents at -
50 mV following the four second test pulses.  Details of the changes in hERG1A 
biophysical characteristics are discussed below and summarized in Table 2. 
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Figure 11. HERG1A current is altered by N-glycans.  Whole cell current traces 
for hERG1A expressed in Pro5, Lec2, Lec1, and N-Glycanase treated Pro5 cells. 
Cells were stepped to increasingly depolarized potentials for 4 s from the -80 mV 
holding potential, and then to -50 mV for 4 s to record the tail current.  
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Table 2. Biophysical parameters for hERG1A as expressed in Pro5, Lec2, 
Lec1, and following N-Glycanase treatment 
 
 
 
Table 2. Data are the mean ± SEM.  Va: Voltage of half-activation.  Ka: Boltzmann 
activation slope factor.  Vi: Voltage of half-inactivation.  Ki: Boltzmann inactivation 
slope factor. * = significance (p<0.05).  
 
 
 
 
 
 
 
 
 
 
 
 
 
hERG1A Channel n Va (mV) Ka (mV) Vi (mV) Ki (mV)
Full Glycosylation 
(Pro5)
11 -22.0 ± 1.3 8.4 ± 0.3 -74.4 ± 4.9 -19.0 ± 0.8
Reduced Sialylation 
(Lec2)
11 -13.7 ± 2.4* 8.6 ± 0.4 -56.2 ± 5.3* -17.2 ± 1.3
Mannose-Rich 
(Lec1)
6 -12.6 ± 2.4* 8.9 ± 0.4 -49.7 ± 5.1* -15.4 ± 1.5*
N-Glycanse treated 
Pro5
3 -9.6 ± 2.2* 8.8 ± 0.4 -58.1 ± 7.7 -20.5 ± 0.6
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N-glycans promote hERG1A voltage-dependent activation 
There is a consistent rightward shift in the current-voltage (I-V) relationships for 
hERG1A under conditions of reduced glycosylation (see Figure 12).  Note that 
the full I-V curves were shifted by a depolarizing 5-10 mV along the voltage axis 
for hERG1A expressed under conditions of reduced sialylation (Lec2), reduced 
complex N-glycosylation (Lec1), and when fully deglycosylated (N-glycanase 
treatment).  These data indicate that N-glycans shift the activation voltage for 
hERG1A to more hyperpolarized potentials. 
 
The hERG1A steady state activation (SSA) relationships are shifted to more 
depolarized potentials under conditions of reduced glycosylation 
To determine more rigorously the impact of N-glycans on hERG1A activation, the 
SSA relationships were determined using tail current analysis (Figures 11 and 
12).  There was a consistent, 8-12 mV depolarizing shift in the SSA relationships 
for hERG1A expressed under each condition of reduced glycosylation (Figure 12, 
Table 2).  As Table 2 indicates, the voltages of half-activation (Va) measured 
were also 8-12 mV more depolarized for less glycosylated hERG1A. The slope 
factors of the SSA relationships, Ka, were unaffected.  This suggests that N-
glycans modulate hERG1A activation causing a linear shift in the SSA 
relationship.   
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Figure 12. HERG1A steady state activation curve is shifted to more 
hyperpolarized potentials with full N-glycosylation.  Current-voltage (I-V) and 
steady state Activation curves for hERG1A expressed in Pro5 (square), Lec2 
(circle), Lec1 (triangle) and N-Glycanase treated Pro5 (upside down triangle) 
cells. Data are mean ± SEM.  Top: IV curves. Lines are point-to-point.  Bottom: 
Steady state Activation (SSA) curves.  Lines are fits of the data to single 
Boltzmann distributions.  Vertical, dotted lines project to the Va for each 
condition. n= 11, 11, 6, 3 (See Table 2). 
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N-glycans act to slow closing of hERG1A  
Time constants for hERG1A deactivation were determined under each condition 
of N-glycosylation.  As observed in Figure 13, the deactivation time constants for 
the fully glycosylated hERG1A are significantly greater than those observed for 
the less glycosylated channels.  This is most notable at less hyperpolarized 
voltages, likely caused by the strong voltage-dependence of hERG1A 
deactivation. 
 
N-glycans cause a greater shift in voltage dependence of steady state channel 
availability  
To determine whether hERG1A channel availability is affected by N-glycans, 
steady state channel inactivation (SSI) curves were measured (Figure 14, Table 
2).  Note the large, significant, depolarizing shift in steady state channel 
availability under conditions of reduced glycosylation (21-30 mV).  Specifically, 
the voltage dependence of half-inactivation (Vi) for hERG1A under conditions of 
reduced sialylation was 21 mV more depolarized than the fully glycosylated 
hERG1A (Table 2).  This depolarization of Vi was larger for hERG1A expressed 
in a mannose-rich state (in Lec1 cells, ~ 30 mV), or following full deglycosylation 
(~22 mV).   The less glycosylated hERG1A channels inactivated at voltages 
significantly more depolarized than the fully glycosylated control channels.  
However, there was no significant difference in Vi measured among the less 
glycosylated channels. 
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Figure 13. N-glycans act to slow hERG1A closing. Top panel: HERG1A 
deactivation time constants as expressed in Pro5 (squares), Lec2 (circle), Lec1 
(triangle), and N-Glycanase treated Pro5 (upside down triangle) cells. Data are 
the mean ± SEM deactivation time constant at a membrane potential.  Lines are 
point-to-point.  Inset:  Sample whole cell currents measured using the 
deactivation protocol.  Lower panel:  Mean ± SEM deactivation times constants 
at -50 mV for Pro5 (small slanted lines), Lec2 (mesh), Lec1 (large slanted lines), 
and N-Glycanase treated Pro5 (horizontal lines) cells. n= 11, 11, 6, 3 (See Table 
2).  Significance (*) was determined by comparing Pro5 with each condition of 
reduced glycosylation (p<0.05). 
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Figure 14. Steady state channel availability is altered by N-glycans. Steady state 
inactivation (SSI) curves for hERG1A expressed in Pro5 (square), Lec2 (circle), 
Lec1 (triangle), and N-Glycanase treated Pro5 (upside down triangle) cells. Data 
are mean ± SEM.  Lines are fits of the data to single Boltzmann distributions. n= 
11, 11, 6, 3 (See Table 1).  Inset:  Typical whole cell inactivating current traces 
from a hERG1A expressing Pro5 cell. 
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The large and variable shift in the voltage-dependence of activation and 
inactivation causes a shift to more physiological potentials and an increase in 
hERG1A window current 
HERG1A activation, deactivation, and inactivation voltage dependence were 
each modulated by changes in the glycosylation state of the channel.  For each 
gating mechanism studied, N-glycans caused a hyperpolarizing shift in the 
voltage dependence of channel gating.  However, the magnitude of the shift in 
steady state activation and inactivation were not uniform; channel availability was 
shifted about twice as much along the voltage axis as was channel activation.  
The combined distribution of channels between the active and inactive states at a 
membrane potential will affect the density of channels that are active at that 
membrane potential.  The area under the overlapping portions of the SSA and 
SSI curves represents the window current, or the voltages at which hERG1 
channels are active.  Figure 15 plots the window currents measured under the 
four conditions of glycosylation.  The bell-shaped curves are the product of the 
two Boltzmann relationships for steady state activation and inactivation, and 
represent the predicted persistent channel activity (Fig. 15B).  Because both the 
activation and inactivation curves shifted to more depolarized potentials for less 
glycosylated channels, the window current will also be shifted to more 
depolarized potentials as observed.  Note that the peak of the window current is 
10-15 mV more depolarized for the less glycosylated hERG1A channels 
compared to the fully glycosylated channels.  In Figure 15C, the peak of each  
50 
 
 
 
 
Figure 15. N-glycans limit hERG1A window currents with persistent hERG1A 
activity at more hyperpolarized potentials.  A: Overlapping SSA and SSI curves 
for hERG1A as expressed in Pro5 (solid line), Lec2 (long dash line), Lec1 (short 
dash line), and N-Glycanase treated Pro5 (dotted line) cells.  Curves are the 
Boltzmann fits from Fig. 12 and Fig. 14.  B:  Predicted window currents for 
hERG1A.  Lines are as described in panel A.  C:  Peak predicted normalized 
window current.   Bar graph comparing the relative magnitude (percent active 
channels) of the peak window current for each condition. 
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curve is greater for the less glycosylated channels, increasing by 1.6 fold for 
Lec2, 2.4 fold for Lec1, and 1.4 fold for enzymatically deglycosylated cells.  This 
suggests an increase in window current with a reduction in N-glycans.  Estimates 
made to determine the area under the curve predict a 1.3-2.5 fold increase in the 
amount of potassium moving across the membrane for the less glycosylated 
hERG1A.  To further examine the hERG1A channel persistent current, the 
steady state currents following a four second pulse to voltages near the I-V peak 
for the less glycosylated channels (0, 10, and 20 mV) showed a 23-80% increase 
in window current compared to fully glycosylated controls (data not shown).  With 
reduced levels of N-glycosylation and sialylation, channels recovering from 
inactivation during the AP would occur at smaller repolarizations and in greater 
numbers, thus increasing the rate of AP repolarization.  Simulation of the 
ventricular AP predicted exactly this change in AP waveform (Fig. 16).  That is, 
simulation of the rightward shift and increase in hERG1A window current caused 
increased phase II/phaseIII repolarization that would lead to reduced AP 
duration.  Thus, additional N-glycans, specifically, sialic acids, would act to limit 
hERG1A activity during the AP causing an increased AP duration as discussed 
later.     
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Figure 16.  in silico modeling predicts ventricular action potential is extended by 
increased N-glycosylation.  Predicted ventricular action potential waveforms, 
assuming hERG1A activity as observed under each condition of glycosylation.  
Computer simulation of the cardiac AP was done in collaboration with Dr. Hui 
Yang, Department of Industrial & Management Systems Engineering, USF. 
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Discussion 
N-Glycans lead to a loss of hERG1A function 
Here we show that N-glycans, particularly sialic acids attached to N-glycans, alter 
gating and kinetics of hERG1A.  Previous work on hERG1A and N-glycosylation 
focused on trafficking and stability of the channel in the membrane59,60.  This 
work represents the first set of data questioning the role of N-glycans on 
hERG1A gating and kinetics.  For all parameters studied, N-glycans shifted 
voltage dependent gating to more negative potentials.  The data show hERG1A 
gating is modulated similarly under three different conditions of reduced 
glycosylation ranging from a modest reduction of sialic acids to the complete 
removal of N-glycans following N-glycanase treatment.  The data show that 
reduced N-glycosylation achieved through expression in Lec2 or Lec1 cells, or 
through enzymatic deglycosylation, each altered channel activation and 
inactivation similarly, with significant rightward shifts in steady-state activation, 
steady-state inactivation, and deactivation kinetics observed for each condition of 
reduced glycosylation.  However, no significant differences in steady-state 
activation or steady-state inactivation were observed among the three conditions 
of reduced glycosylation.  This suggests that the sialic acids attached to hERG1A 
N-glycans are responsible for the majority of the effect of N-glycans on channel 
function.   
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While the direct effects of changes in channel glycosylation are similar to our 
previous work on voltage-gated Na+ and K + channels, the impact on AP 
waveform with such changes in glycosylation are novel – channel N-glycans limit 
hERG1A activity, thereby acting to extend the cardiac AP.  The rightward shifts 
seen for both steady-state activation and inactivation under each condition of 
reduced glycosylation would lead to a depolarizing shift in channel window 
current (Fig. 15A).  The larger rightward shift in the inactivation curve would also 
cause an increase in the magnitude of the window current (Fig. 15B).  For less 
glycosylated hERG1A channels, a greater number of channels would be re-
activated at depolarized potentials (less repolarized) compared to the fully 
glycosylated channels.  That is, the reduction in hERG1A glycosylation or 
sialylation leads to a gain of hERG1A function.  The positive feedback nature by 
which hERG1A reactivates would lead to the rapid recovery of hERG1A, and 
further increase K+ efflux at earlier times during the AP, and likely reduce AP 
duration as observed through simulation of the ventricular AP (Fig. 16).  As will 
be discussed in detail below, as channel sialylation is regulated, or when it is 
aberrant, hERG1A activity will change, thereby impacting AP repolarization. 
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CHAPTER 4 
PENCILLIN BLOCK OF HERG1A 
HERG1A blockade by a range of drugs is linked to acquired long QT syndrome 
(aLQTS)35,41,46,48-50,99.  This results in an increased risk of sudden death from 
ventricular arrhythmias.  Several medications have been withdrawn from the 
pharmaceutical market due to causing QT prolongation100,101.  The successful 
development of potential new drug therapies hinges on finding drugs that do not 
induce cardiac arrhythmias.  The most common problem in acquired long QT 
syndrome is blocking hERG1A, delaying cardiac repolarization and increasing 
the risk of torsades de pointes (TdP).  
 
Previously, it was known that some medications that were used to treat cardiac 
arrhythmias were also considered proarrhythmic.  The Cardiac Arrhythmia 
Suppression Trial (CAST) of 1991 investigated class I anti-arrhythmic agents that 
blocked NaV channels and reduced conduction velocity of electrical impulses in 
the ventricular myocardium.  It became apparent that non-cardiac drugs, 
including antibiotics, antipsychotics, antidepressants and antimalarials, can also 
cause TdP.  TdP is a twisting of the QRS complex around the isoelectric line of  
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the body-surface electrocardiogram (ECG) and leads to an increased incidence 
of sudden death. 
 
Once it was known that non-cardiac drugs could block hERG1A and potentially 
alter the cardiac AP, a flood of research went into understanding what can block 
hERG1A and how to deduce new structures that would be anti-arrhythmic. 
Understanding what current drugs on the market block hERG1A and at what 
concentrations is essential to correctly prescribing medications to patients. 
 
The discovery of penicillin is attributed to Scottish scientist and Nobel laureate 
Alexander Fleming in 1928 (see Figure 17).  This observation began the modern 
era of antibiotics. Penicillin is a β-lactam antibiotic.  It works by inhibiting the 
formation of peptidoglycan cross-links in the bacterial cell wall. 
 
The mechanism of action of penicillin at the molecular level starts with the 
binding of penicillin to penicillin-binding proteins (PBPs) which are located in the 
cell wall.  Some PBPs are inhibitors of cell autolytic enzymes that literally eat the 
cell wall and are most likely necessary during cell division.  Other PBPs are 
enzymes that are involved in the final step of cell wall synthesis called 
transpeptidation.  These enzymes are outside the cell membrane and link cell 
wall components together by joining glycopeptide polymers together to form 
peptidoglycan.  The bacterial cell wall owes its strength to layers composed of  
57 
 
 
 
 
 
 
Figure 17. Structure of Penicillin G.  Molecular structure of Penicillin G. Formula 
weight for Penicillin G is 334 g/mol. pKa is~3. 
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peptidoglycan.  This is a complex polymer composed of alternating N-
acetylglucosamine and N-acetylmuramic acid as a backbone from which a set of 
identical tetrapeptide side chains branch, and a set of identical peptide cross-
bridges also branch.  The tetrapeptide side chains and the cross-bridges vary 
from species to species, but the backbone is the same in all bacterial species. 
Each peptidoglycan layer of the cell wall is actually a giant polymer molecule 
because all peptidoglycan chains are cross-linked. In gram-positive bacteria 
there may be as many as 40 sheets of peptidoglycan, making up to 50% of the 
cell wall material.  In gram-negative bacteria, there are only one or two sheets 
(about 5-10% of the cell wall material).  Penicillin G has high activity against 
gram-positive bacteria and low activity against gram-negative bacteria. 
 
Penicillin acts by inhibiting peptidoglycan synthesis by blocking the final 
transpeptidation step in the synthesis of peptidoglycan.  It also removes the 
inactivator of the inhibitor of autolytic enzymes, and the autolytic enzymes then 
lyse the cell wall, and the bacterium ruptures.  This latter is the final bacteriocidal 
event. 
 
Penicillin G was the first discovered penicillin in what is now a long list of 
penicillins.  It is absorbed orally with about 2/3 of the dose being degraded by 
stomach acids.  Penicillin G is very susceptible to beta lactamases, enzymes 
which inactivate the compound by degrading the beta-lactam ring.  All penicillins 
59 
 
are acidic drugs that are acid labile and will degrade in neutral or basic solutions. 
The degradation opens the beta-lactam ring and results in inactivation of the 
penicillin.  Penicillins are generally safe, having low toxicity, and can be used in 
pregnancy and during lactation.  Penicillin G is considered a short acting drug.  
After oral administration, penicillin is absorbed mainly from the duodenum and 
upper jejunum.  The extent of absorption depends on the presence of food in the 
gastrointestinal tract, gastric and intestinal pH and the relative acid-stability of the 
penicillin derivative.  Penicillin G is acid-labile and should be taken on an empty 
stomach.  Peak serum levels are reached within 30 to 60 minutes. 
 
Penicillins are readily distributed into ascitic, synovial, pleural and pericardial 
fluids.  Distribution into tissues varies widely, with highest amounts in the kidney 
and lower concentrations in the liver, lungs, skin, intestines and muscle.  Small 
amounts are found in all other body tissues and in the CSF.  When the meninges 
are inflamed, the CSF concentration is about 5% of the serum concentration and 
can be therapeutic against sensitive organisms.  Penicillins readily cross the 
placenta and are distributed into breast milk.  In patients with normal kidney 
function, penicillin is excreted rapidly by filtration and active tubular secretion. 
The elimination half-life is about 30 minutes. 
 
HERG1A has been shown to be blocked by numerous antibiotics, including 
erythromycin, sulfa drugs, and grepafloxacin.  Grepafloxacin has been removed 
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from the market due to QT prolongation and death.  With all of the studies being 
done on hERG1A drug block, no one has published any findings on the very first 
antibiotic, Penicillin G.  Here, we show that Penicillin G blocks hERG1A102. 
 
Results 
To determine whether Penicillin G blocks hERG1A, hERG1A was expressed in 
the fully glycosylated Pro5 cell line.  Pro5 cells were exposed to three different 
concentrations; 10 µg/mL, 50 µg/mL, and 200 µg/mL.  Penicillin G was perfused 
at 0.5 mL/min using the typical extracellular solution as the vehicle.  Since 
Penicillin G is readily absorbed, we did not need to add it to the intracellular 
solution.  Five minutes of equilibration time was allowed before recording. All 
recordings were conducted while perfusing on solution. 
 
HERG1A is blocked by Penicillin G 
Initially, we were using Penicillin G as a potential negative control, since 
extensive literature searches yielded no reports on Penicillin block of hERG1A. 
What was found was that, at therapeutic concentrations, hERG1A function was 
blocked by Penicillin G (see Figure 18).  Maximal conductance of the 10, 50, and 
200 µg/mL concentrations were normalized to the zero concentration.  Figure 19 
is a bar graph reflecting the % block at each concentration. 
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Figure 18. Current trace at +20 mV for hERG1A at multiple drug concentrations.  
Current trace showing block of hERG1A activity by Penicillin G at each 
concentration tested (30 µM, 150 µM, and 600 µM).   
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Figure 19. Percent block by Penicillin G. The total block by Penicillin G increases 
with increasing concentrations of the drug.  The high concentration of Penicillin G 
shows a 35% block of hERG1A current. 
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Discussion 
For the first time, it was shown that Penicillin G blocks hERG1A function at 
therapeutic concentrations.  With more than 1/3 of hERG1A function blocked at 
the 200 µg/mL concentration, the normal AP could be seriously compromised.  
This blockade of hERG1A could potentially alter the cardiac action potential and 
cause an acquired QT prolongation. 
 
Although this is the first report that shows Penicillin G blocks hERG1A function, 
we cannot overlook the fact that others have not shown any harmful side effects 
of Penicillin G on cardiac function.  There could be multiple reasons. 
 
The first rationale is Penicillin G can be harmful when administered to patients. 
Either no one has cited problems in the literature or these concerns have not 
been attributed to hERG1A blockade.  Although Penicillin G is a good antibiotic, it 
does have its drawbacks.  It is short acting and can easily be inactivated by 
stomach acid.  Normal administration of the drug is by injection.  Even then, 
Penicillin G is not used as readily as other antibiotics (many have an allergy to it). 
As a result, there may not be enough data to confer whether there are dangerous 
consequences to Penicillin G use. 
 
The second point goes back to remodeling.  The body has a wonderful way of 
adapting to changes and unsafe environments.  Penicillin G may block hERG1A, 
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but that does not mean it will automatically cause QT prolongation.  There are 
multiple channels at work during the repolarization phase of the cardiac AP.  
These additional sodium, calcium, and potassium channels may be up-regulated 
or altered to balance out the blockade of hERG1A.  Consequently, hERG1A may 
be altered itself to change how a drug blocks it or how it works during the AP. 
 
The third concern is that the harmful effects of hERG1A blockade are not seen 
considering the half-life of Penicillin G is around thirty minutes.  This may not be 
adequate time for the drug to reach the heart and cause hERG1A dysfunction. 
Additionally, it may reach the heart, but the thirty minute timeframe is not 
sufficient to cause block of the channel.  We show that direct application of the 
drug to the outside of the cell for as little as five minutes is ample time to cause 
block even with a low concentration of 10 µg/mL.  However, cell expression 
systems do not completely replicate events occurring in-vivo.  They are merely 
an excellent tool to begin looking at a question.  Additional studies should be 
conducted to properly comprehend the blockade of hERG1A by Penicillin G. 
 
Any alterations in the cardiac action potential can be harmful.  Penicillin G can 
now be added to the long list of drugs that block hERG1A function.  These 
changes will likely have a detrimental effect on normal cardiac rhythm.  This 
could result in arrhythmias, TdP, and sudden cardiac death. 
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CHAPTER 5 
N-GLYCANS ALTER ANTIBIOTIC BLOCK OF HERG1A 
In the last ~12 years, significant efforts were made to inform the world of 
“Acquired LQTS Risk”.  As a result, three important guidelines were released 
named the Points to Consider document, ICH S7A and ICH S7B guidelines.  The 
Points to Consider document was released in 1997 by the Committee for 
Proprietary Medicinal Products (CPMP).  It stated facts about the assessment of 
QT prolongation by non-cardiac medications.  This was the beginning of global 
understanding of potential dangers of new and current drugs that has forced 
pharmaceutical companies to establish an improved cardiac safety profile.  In 
2000, the ICH S7A guideline was introduced by the International Conference of 
Harmonization (ICH).  The S7A guideline was titled, “SAFETY 
PHARMACOLOGY STUDIES FOR HUMAN PHARMACEUTICALS”.  It is a 
thirteen page document whose objective is to protect participants and patients of 
clinical trials from potentially adverse effects of pharmaceuticals, while avoiding 
unnecessary resources and animal use.  The guideline goes on to dictate the 
tests needed to be done for all of the physiological systems in the body.  The ICH 
S7B guideline called, “THE NON-CLINICAL EVALUATION OF THE POTENTIAL 
FOR DELAYED VENTRICULAR REPOLARIZATION (QT INTERVAL 
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PROLONGATION) BY HUMAN PHARMACEUTICALS”, was released by the ICH 
in 2005.  This guideline describes a non-clinical testing strategy for assessing the 
potential of a test substance to delay ventricular repolarization (see Figure 20). 
This guideline includes information concerning non-clinical assays and integrated 
risk assessments.  The ICH S7B expands upon the ICH S7A guideline.  The 
objective of the newest guideline is to identify whether a test substance has the 
potential to delay ventricular repolarization and to correlate the extent of delayed 
ventricular repolarization to the concentrations of the test substance.  The results 
can be used to reveal a mechanism of action and potentially estimate risk for 
delayed ventricular repolarization and QT interval prolongation in humans.  The 
ICH S7B is a preclinical safety strategy that all pharmaceutical companies 
comply with.  The first step in this strategy is called the “golden standard” which 
is an in vitro IKr assay to test for potential hERG interactions by means of patch 
clamp studies.  Taken as a whole, these documents assess and set forth steps 
that pharmaceutical companies take to establish a safety profile regarding 
cardiac events for all new drug candidates and already marketed drugs that have 
been found to have adverse clinical events, a new patient population, or a new 
route of administration raises concerns not previously addressed. 
 
Hundreds of drugs have been found to directly affect the ventricular repolarizing 
current, IKr, reduce K+ efflux, and lead to an arrhythmia
35,54,55,103-105.  This toxicity 
is widespread, as indicated by analysis of a drug-monitoring database 
67 
 
 
 
 
 
 
Figure 20. ICH S7B guideline. The ICH S7B guideline dictates strategies for 
testing pharmaceutical drug candidates for possible arrhythmic events. 
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maintained by the World Health Organization106-108.  This is why the ICH S7B 
guideline requires an in vitro assay on the main repolarizing current to test for 
potential drug interactions.  It has been found that 2-9% of patients taking 
quinidine, an antiarrhythmic, produces TdP46.  As a result, there have been 
certain drugs taken off the market.  From 1997 to 2000, three drugs were 
removed from patient use.  The first drug, Terfenadine, was in 1997.  It is an 
antihistamine formerly used for the treatment of allergic conditions.  Terfenadine 
is a prodrug, generally completely metabolized to the active form fexofenadine by 
intestinal CYP3A4.  Terfenadine itself, however, has a cardiotoxic effect and may 
be absorbed and reach myocytes if the patient is concurrently taking a CYP3A4 
inhibitor (e.g. erythromycin or grapefruit juice).  In 1999, Grepafloxacin, an 
antibiotic, was removed from the market due to increased QT prolongation.  This 
antibiotic is in a class of drugs called fluoroquinolones and fights bacteria in the 
body.  In 2000, Cisapride was withdrawn because of reports of causing Long QT 
in patients.  Cisapride is a parasympathomimetic which acts as a serotonin 5-
HT4 agonist.  It is used for the symptomatic treatment of patients with nocturnal 
heartburn due to gastroesophageal reflux disease.  Cisapride was associated 
with 270 adverse cardiac effects, specifically cardiac arrhythmias, and there have 
been 70 fatal reactions. 
 
To better understand how IKr is altered by drug block, we need to understand 
how hERG1A is blocked by a drug.  Figure 21 describes the potential  
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Figure 21. Potential hERG1A block by antibiotics. Drugs can block hERG1A 
several ways; 1) from the outside (in the case of SMX) and 2) from the inside, 
interacting with the aromatic structures (as does Erythromycin).  The mechanism 
that Penicillin G uses to block hERG1A has not yet been elucidated. 
 
 
 
 
70 
 
mechanisms to how a drug can block hERG1A.  The most common areas are 
either outside or inside the cell. 
 
Blocking the flow of potassium through hERG1A from the outside of the cell is 
not fully understood.  Most work has been completed with divalent cations, since 
so many reduce hERG current109-112.  One thought is that the drug (divalent 
cation) may physically occlude the pore region, essentially sitting in the opening 
of the extracellular side of the channel.  Since hERG1A is inactivated by C-type 
inactivation, it is thought that the external side of the pore for hERG1A is larger 
than other K+ channels. 
 
Another externally oriented blocking mechanism may involve the acidic residues 
on the S2 and S3 segments, specifically D226 and D456, along with the first four 
arginine residues on S4.  These residues work together during the activation and 
deactivation of the channel through an electrostatic interaction.  The divalent 
cations may bind to or screen sites on the hERG1A channel altering the negative 
electrostatic potential causing alterations to the gating and kinetics of hERG1A, 
thereby modulating current.  This mechanism is called a surface charge theory.   
 
An additional theory is the voltage-dependent block theory where the drug 
binding site is within the pore and the drug must cross part of the electric field of 
the membrane to block hERG1A.  Because the drug must cross the electric field 
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the binding and unbinding is voltage-dependent.  Drugs are not limited to utilizing 
one of these theories, but can use a combination of any of the theories. 
 
As for block from the intracellular side, it has been shown that hERG1A has 
structural features that assist the binding of drugs better than other K+ channels.  
HERG1A channels are blocked by drugs with diverse structures that cover 
several drug classes, including antiarrhythmic, psychiatric, antimicrobial and 
antihistamine48,110,113,114.  Because of this unusual susceptibility to blockage by 
drugs, it is thought that hERG1A has multiple unique binding sites. An Ala-
scanning mutagenesis approach was used to identify residues of hERG1A that 
interact with several drugs inside the pore region.  Residues within the pore were 
individually mutated  and then evaluated for sensitivity to potent hERG1A 
blockers50,115.  Mutation of multiple residues (Thr 623, Ser 624, Val 625, Gly 648, 
Tyr 652 and Phe 656) located in the S6 domain of the hERG1A subunit lowered 
the affinity of multiple drugs, including MK-499, a potent anti-arrhythmic.  The 
same residues were found to be important for binding of cisapride, terfenadine 
and several other drugs from different chemical classes55.  Tyr 652 and Phe 656 
have side chains that are essential for drug block.  These aromatic residues are 
turned toward the center of the channel only when the channel is open, which is 
consistent with hERG1A being blocked after the channel has opened.  It has 
been reported that drugs block hERG1A in a state-dependent manner and most 
have been shown to not block the channel in its closed state116.  Conceivably, the 
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multiple aromatic side chains (eight per channel), will accommodate multiple 
interactions by numerous drugs. 
 
Reduction in or reduced IKr can lead to drug-induced arrhythmias.  The drugs that 
block hERG1A encompass almost every class of drugs on the market.  These 
drugs are known to elongate the repolarization phase, including many 
antibiotics24,28,35,41,46,49,117-121.  We chose to look at antibiotics for many reasons:  
1) antibiotics are given to both men and women, 2) they are prescribed to 
patients of all age groups from young to elderly, 3) antibiotics are provided to 
individuals for many different diseases, and 4) hERG1A mutations can alter the 
susceptibility of the channel complex to many drugs.  The Sesti group 
documented an increase in drug block of the hERG1/MiRP1 channel complex by 
SMX when the complex was formed with a mutated MiRP1 subunit119,121.  The T 
to A mutation disrupts the NXS/T consensus site for N-linked glycosylation.  
Although this mutation is not associated with inherited LQTS and it does not alter 
the formation of the hERG1/MiRP1 complex, the polymorphism is implicated in 
drug-induced arrhythmias. 
 
To decide what antibiotics to investigate, we examined how a drug blocks the 
channel.  As described earlier, there are multiple ways to block hERG1A (see 
Figure 21).  Sulfamethoxazole (SMX) was selected since it may block hERG1A 
extracellularly, apparently similarly to how many divalent cations block the 
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hERG1A pore119.  Erythromycin was chosen because it is believed to block the 
hERG1A channel intracellularly and increasing concentrations of Erythromycin 
cause a severe decrease in hERG1A current and an alteration in the voltage 
dependence of channel block35,41.  Penicillin G had not been shown to block the 
hERG1A channel until our findings (summarized in chapter 4).  However, 
Ampicillin, an analog to Penicillin, was revealed to prolong the QT interval during 
anaphylaxis to the prescribed antibiotic99.  The cardiac abnormalities subsided 
after a few days.  We thought to use Penicillin G to test whether a drug that has 
no known inhibition of hERG1A can become an inhibitor under conditions of 
altered glycosylation.  Our studies found Penicillin G does inhibit hERG1A 
function and therefore cannot be used as a negative control. 
 
Sulfamethoxazole (SMX) is a sulfonamide bacteriostatic antibiotic (see Figure 
22).  Its primary activity is against susceptible forms of Streptococcus, 
Staphylococcus aureus, Escherichia coli, Haemophilus influenzae, and oral 
anaerobes.  It is primarily used to treat urinary tract infections and can be used 
as an alternative to amoxicillin-based antibiotics to treat sinusitis.  Sulfonamides 
are structural analogs and competitive antagonists of para-aminobenzoic acid 
(PABA).  They inhibit normal bacterial utilization of PABA for the synthesis of folic 
acid, an important metabolite in DNA synthesis.  Folic acid is not synthesized in 
humans, but is instead a dietary requirement.  This allows for the selective 
toxicity to bacterial cells (or any cell dependent on synthesizing folic acid) over  
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Figure 22. SMX block of hERG1A. The top panel displays the molecular 
structure for SMX. The molecular weight is 290 g/mol and the pKa is ~5.7.  The 
bottom panel is a typical current trace at +20 mV showing a reduction in hERG1A 
current at the following concentrations: 172 µM, 1 mM, and 2 mM. 
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human cells.  Bacterial resistance to SMX is caused by mutations in the folic acid 
enzyme that inhibit PABA from binding and block folic acid synthesis.  
Sulfamethoxazole is typically prescribed to adults and children, to treat 
bronchitis, middle ear infections, and urinary tract infections.  The dosage for an 
adult (above 88 lbs.) is 800 mg every 12 hours, while the dosage for a child 
(weighing less than 88 lbs.) is 9-13 mg per pound every 12 hours. 
 
Eli Lilly’s research team isolated Erythromycin from the metabolic products of a 
strain of Saccharopolyspora erythraea found in soil samples in 1949 (see Figure 
23).  Lilly filed for patent protection of the compound and U.S. patent 2,653,899 
was granted in 1953.  The product was launched commercially in 1952 under the 
brand name Ilosone.  Erythromycin was formerly also called Ilotycin.  
Erythromycin is a macrolide antibiotic that has an antimicrobial spectrum similar 
to or slightly wider than that of penicillin, and is often used for people who have 
an allergy to penicillins.  For respiratory tract infections, it has better coverage of 
atypical organisms, including mycoplasma and Legionellosis.  Its structure 
contains a 14-membered lactone ring with ten asymmetric centers and two 
sugars (L-cladinose and D-desoamine), making it a compound very difficult to 
produce via synthetic methods. The first synthetic form “A” was not accomplished 
until the 80’s.  Erythromycin inhibits the cytochrome P450 system which has the 
potential of affecting the metabolism of many different drugs.  If CYP3A4 
substrates are taken with erythromycin, the levels of the substrates of these  
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Figure 23. Erythromycin blocks hERG1A. The top panel displays the molecular 
structure for Erythromycin. The molecular weight is 734 g/mol and pKa is ~8.8.  
The bottom panel is a typical current trace at +20 mV showing a reduction in 
hERG1A current at the following concentrations: 34µM, 136 µM, and 272 µM. 
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drugs could increase often causing adverse effects.  Erythromycin is easily 
inactivated by gastric acid and is normally administered as an enteric-coated 
tablet.  It is very rapidly absorbed, and diffuses into most tissues and phagocytes. 
Due to the high concentration in phagocytes, erythromycin is actively transported 
to the site of infection where large concentrations of erythromycin can be 
released.  Erythromycin is typically prescribed to adults and children to treat strep 
throat and Legionnaires disease.  The dosage for an adult is 250-500 mg every 
6-12 hours, while the dosage for a child is 3.4-5.6 mg per pound every 6 hours or 
6.8-11.4 mg per pound every 12 hours.  The typical serum levels range from 4-40 
µM. 
 
Penicillin is a group of antibiotics derived from Penicillium fungi (see Figure 24).  
Penicillin antibiotics are historically significant because they are the first drugs 
that were effective against many previously serious diseases such as syphilis 
and Staphylococcus infections.  Penicillins are still widely used today, though 
many types of bacteria are now resistant.  All penicillins are Beta-lactam 
antibiotics and are used to treat bacterial infections.  The term "penam" is used to 
describe the core skeleton of a member of a penicillin antibiotic.  This skeleton 
has the molecular formula R-C9H11N2O4S, where R is a variable side chain.  
Penicillin is typically prescribed to adults and children, to kill bacteria or prevent 
bacterial growth.  The dosage for an adult is 200,000-500,000 U (125-312 mg)  
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Figure 24. Penicillin G blocks hERG1A. The top panel displays the molecular 
structure for Penicillin G.  The bottom panel is a typical current trace at +20 mV 
showing a reduction in hERG1A current at the following concentrations: 30 µM, 
150 µM, and 600 µM. 
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every 4-6 hours, while the dosage for a child is 189-13,636 U per pound every 4-
8 hours. 
 
Our earlier work, summarized in chapter 3, demonstrated that N-glycans limit 
hERG1A activity.  We want to better understand how these alterations in N-
glycans may impact antibiotic block of the channel.  Utilizing the CHO cell 
expression system of Pro5, Lec2, and Lec1 cells, we delivered different 
concentrations of three antibiotics individually to the hERG1A channel to 
determine whether and how changes in N-glycosylation modulate antibiotic block 
of hERG1A.  The data indicate that N-glycans play a protective role on hERG1A 
antibiotic block122.  Also, hERG1A block was never lessened by conditions of 
reduced N-glycosylation. 
 
Results 
SMX block is altered by N-glycans 
SMX is thought to block hERG1A extracellularly.  A competitive inhibition study 
done with SMX and cadmium showed that SMX blocks hERG1A in a similar 
fashion to cadmium119.  The hERG1A N-glycosylation structures reside in the P 
loop.  With the CHO cell expression system, we tested whether changes in N-
glycans affected block of hERG1A.  The data show decreases in N-glycosylation 
caused an increase in hERG1A block (see Figure 25).  If sialic acids are absent 
from the N-glycan structure, an increase in maximum block is seen for the low  
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Figure 25. Concentration dependent block by SMX. Top panel: Percent block of 
hERG1A current by SMX at each concentration tested. Bottom Panel: Dose-
response curve of SMX.  * is significant (p < 0.05). 
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(50 µg/mL), mid (300 µg/mL) and high (600 µg/mL) concentrations.  Interestingly, 
when the complex N-glycosylation is absent, there is also a significant increase 
in SMX block for every concentration tested.  These data suggest that sialic acids 
play a protective role on hERG1A block by SMX at saturating depolarizations.  
The data also suggest that complex N-glycans may provide additional protection 
against SMX block. 
 
Erythromycin block is modified by complex N-glycans 
Erythromycin has been a heavily researched drug relative to hERG1A block.  It 
has been linked to arrhythmias in individuals and shown to be pro-arrhythmic by 
blocking hERG1A.  The studies completed on Erythromycin conclude that the 
aromatic residues on the S6 segment interact with the drug and block hERG1A 
from the inside35,55,105.  We questioned whether changes in N-glycosylation alters 
Erythromycin block.  The data indicate that alterations in N-glycans modify block 
of hERG1A by Erythromycin (see Figure 26).  For channels that are fully 
glycosylated or missing sialic acids, a similar 10-15 % block was observed at 25 
µg/mL.  However, the Lec1 cells expressing hERG1A show a 20 % significant 
block at the low concentration.  As the Erythromycin concentration was 
increased, no significant difference in block was observed among conditions.  
This suggests that a saturating effect may occur.  That is, regardless, of the N-
glycans attached, Erythromycin will block hERG1A.  This might not be surprising 
since it is well established that Erythromycin blocks hERG1A from the inside.   
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Figure 26. Concentration dependent block by Erythromycin. Top panel: Percent 
block of hERG1A current by Erythromycin at each concentration tested. Bottom 
Panel: Dose-response curve of Erythromycin.  * is significant (p < 0.05). 
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Perhaps, the impact of extracellular N-glycans on intracellular block is a minor 
effect.  Keep in mind that there was a small, but significant protective effect of N-
glycans on Erythromycin block at the low concentration.  If the N-glycans are in 
the extracellular pore region, how do they protect against drug block from the 
inside?  There could be many possible explanations for this that include, 1) N-
glycan structures can be rather large and the bulky structure may dip down 
farther into the pore region affecting the surrounding area, and 2) hERG1A N-
glycosylation may alter the channel structure within the plasma membrane.  If the 
channel structure is altered by reduced complex N-glycans, the aromatic 
structures might be more or less accessible to drugs that will block hERG1A. 
 
N-glycans alter Penicillin G block of hERG1A 
In chapter 4, we showed that Penicillin G blocks the hERG1A channel in a 
concentration dependent manner.  Here, we asked whether alterations in N-
glycosylation impact Penicillin G block at the following concentrations: 10 µg/mL, 
50 µg/mL, and 200 µg/mL.  A decrease in sialic acids significantly increase the 
block by Penicillin G at every concentration tested (see Figure 27).  The Lec1 
cells expressing hERG1A show a greater block than control, but this does not 
reach significance until the high concentration.  These data suggest that sialic 
acids account for alterations in Penicillin G block on hERG1A.  Interestingly, at 
the high concentration of Penicillin G, we see equal block between the Lec2 and 
Lec1 suggesting that the sialic acids play a significant role in hERG1A block. 
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Figure 27. Concentration dependent block by Penicillin G. Top panel: Percent 
block of hERG1A current by Penicillin G at each concentration tested. Bottom 
Panel: Dose-response curve of Penicillin G.  * is significant (p < 0.05). 
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Overall block by SMX, Erythromycin, and Penicillin G is different for each 
antibiotic and N-glycans alter the block uniquely for each drug.  This is the 
measured overall blocking ability of hERG1A at maximized depolarizations. 
However, achieving maximum depolarizations may not occur for all cells at 
similar times during the AP and may not even be consistent among ventricular 
myocytes.  Thus, we sought to question whether there is an effect of N-glycans 
on hERG1A block at less depolarizing potentials (less than maximum 
depolarizations).  In order to do this, drug block at -40, -30, -20, and -10 mV was 
measured. 
 
N-glycans modulate SMX block at small depolarizations 
HERG1A block by SMX at each concentration is shown in figures 28-30.  There 
are several interesting, significant phenomenon that can be gleaned from this 
data.  When hERG1A is expressed in Lec2 cells, SMX block, at small 
depolarizations, is greater than when the channel is fully glycosylated.  The 
increase in drug block was seen at every concentration of SMX.  Note for the 
Lec2 and Lec1 cell lines, there is no change in block with membrane potential.  
This is quite different than that observed in the Pro5 cells.  That is, apparently, 
SMX blocks hERG1A in the absence of sialic acids and complex N-glycans in a 
voltage-independent manner.  For the Lec1 expressing hERG1A cells, an 
increase in SMX block was also observed when compared to fully glycosylated 
channels.  These data suggest that sialic acids have the greater impact 
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Figure 28. 50 µg/mL SMX block at small depolarizations. % block by SMX at 
small depolarizations (-40, -30, -20, and -10 mV) for the 50 µg/mL concentration. 
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Figure 29. 300 µg/mL SMX block at small depolarizations. % block by SMX at 
small depolarizations (-40, -30, -20, and -10 mV) for the 300 µg/mL 
concentration. 
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Figure 30. 600 µg/mL SMX block at small depolarizations. % block by SMX at 
small depolarizations (-40, -30, -20, and -10 mV) for the 600 µg/mL 
concentration. 
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on SMX block at small depolarizations than complex N-glycosylation.  These 
data suggest that the negative charges alter the mechanism of SMX block, 
specifically its voltage-dependence. 
 
Complex N-glycans impact Erythromycin block at small depolarizations 
The previous data showed a small, but significant increase in overall 
Erythromycin block of hERG1A at the low Eyrthromycin concentration, but only 
for the Lec1 cells.  However, no other significant effect of N-glycans on overall 
Erythromycin block was observed.  Interestingly, at small depolarizations (-40, -
30, -20, and -10 mV), Lec1 cells expressing hERG1A show a large and 
significant increase in Erythromycin block compared to Pro5 cells expressing 
hERG1A.  In fact, the Pro5 cells show no block from -40 to -20 mV (see Figures 
31-33).  Pro5 and Lec2 cells expressing hERG1A show the same voltage-
dependence, and still, the block by Erythromycin is greater in the Lec2 cells then 
the Pro5 cells.  These data are consistent with the removal of sialic acids is not 
enough to alter voltage-dependent block of Erythromycin, but an increase in 
block is still evident.  In addition, the removal of complex glycosylation greatly 
increase the Erythromycin block of hERG1A and may alter voltage dependent 
block. 
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Figure 31. 25 µg/mL Erythromycin block at small depolarizations. % block by 
Erythromycin at small depolarizations (-40, -30, -20, and -10 mV) for the 25 
µg/mL concentration. 
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Figure 32. 100 µg/mL Erythromycin block at small depolarizations. % block by 
Erythromycin at small depolarizations (-40, -30, -20, and -10 mV) for the 100 
µg/mL concentration. 
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Figure 33. 200 µg/mL Erythromycin block at small depolarizations. % block by 
Erythromycin at small depolarizations (-40, -30, -20, and -10 mV) for the 200 
µg/mL concentration. 
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Sialic acid and complex N-glycans block Penicillin G at small depolarizations 
Overall, hERG1A Penicillin block is greater when fewer N-glycans are present 
(see Figures 34-36).  At small depolarizations, fully glycosylated cells show no 
block at -40 and -30 mV for every concentration of Penicillin G.  The Lec2 cells 
expressing hERG1A show a large and significant block by Penicillin at every 
voltage (-40 to -10 mV) compared to the Pro5 expressing hERG1A cells.  
Interestingly, the Lec1 cells show a Penicillin G block that shifts with 
concentration.  At the low concentration of drug, the Lec1 cells mimic the Pro5 
cells with regard to voltage-dependence, even though the block is still greater in 
the Lec1 cells.  At the high concentration, the Lec1 cells mimic the Lec2 voltage 
dependence and the block is not different between the Lec2 and Lec1 cells.  The 
sialic acids absent from hERG1A alter block (at small depolarizations) by 
Penicillin G greater than any other N-glycan structure.  The additional absence of 
complex glycosylation was not effective in altering voltage-dependence more 
than the sialic acids. 
 
Discussion 
Overall, N-glycosylation plays a protective role for hERG1A against antibiotic 
block.  The data show significantly less antibiotic block when N-glycans are 
present.  For all measurements tested (3 antibiotics at 3 concentrations each at 
more than 5 different voltages and under two different conditions of reduced N-
glycosylation), never was the block under conditions of reduced glycosylation 
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Figure 34. 10 µg/mL Penicillin G block at small depolarizations. % block by 
Penicillin G at small depolarizations (-40, -30, -20, and -10 mV) for the 10 µg/mL 
concentration. 
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Figure 35. 50 µg/mL Penicillin G block at small depolarizations. % block by 
Penicillin G at small depolarizations (-40, -30, -20, and -10 mV) for the 50 µg/mL 
concentration. 
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Figure 36. 200 µg/mL Penicillin G block at small depolarizations. % block by 
Penicillin G at small depolarizations (-40, -30, -20, and -10 mV) for the 200 µg/mL 
concentration. 
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significantly less than that observed under conditions of “full” N-glycosylation.  
Interestingly, block at small depolarizations for SMX, Erythromycin, and Penicillin 
are impacted by changes in glycosylation.  N-glycans may alter the voltage-
dependence of block in different ways depending on the antibiotic.  A lack of 
sialic acids, and the negative charge associated with it, can render block to be 
voltage-independent for SMX.  This is consistent with the thought that SMX 
blocks hERG1A from outside the cell (see Figure 37).  The negative sialic acids 
may have the ability to interact more with SMX since the N-glycans sit in the pore 
region.  The negative sialic acid residues on the terminal ends of the N-
glycosylation structures may impact SMX block, since SMX is negatively charged 
at physiologic pH, by altering the surface charge (or repelling the drug itself).  
When sialic acid are absent from hERG1A, SMX may have the ability to more 
readily bind to its site of action because this site is available. 
 
Erythromycin block is apparently not affected by changes to the surface charge, 
but may be affected by removal of complex N-glycans.  Erythromycin has been 
shown to interact with the aromatic structures deep in the pore region and 
probably blocks hERG1A from inside the cell (Figure 38).  This mechanism of 
block may be too distant from the surface charges outside the channel to 
observe an effect.  Nevertheless, the complex N-glycans may potentially change 
a structural element of hERG1A, thereby altering the affinity of a drug for its 
binding site. 
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Figure 37. Model of extracellular block on hERG1A 
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Figure 38. Model of intracellular block on hERG1A 
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Penicillin G block was altered with changes to glycosylation, and a concentration-
dependent, voltage-dependence was seen for the Lec1 cells expressing 
hERG1A.  HERG1A expressed in the Lec2 cells showed an increase in block at 
the small depolarizations.  It is not known what mechanism Penicillin G uses to 
block hERG1A.  Based on the findings that Penicillin G block is altered by both 
sialic acids and complex N-glycosylation, there is still an uncertainty as to how it 
blocks hERG1A.  However, at physiologic pH, Penicillin G is highly charged and 
would not transverse the lipid bilayer suggesting that Penicillin G may only block 
from the outside (Figure 37).  The data suggest that sialic acid residues play the 
biggest role in altering block by Penicillin G in these studies, possibly by repelling 
or altering Penicillin G’s ability to interact with hERG1A because of the negative 
charges on both Penicillin G and sialic acid.  This implies that Penicillin G may 
block hERG1A similarly to SMX utilizing the surface charge theory of block. 
 
As discussed in chapter 3, alterations in glycosylation affect gating and kinetics 
of hERG1A.  These changes in N-glycan structures also alter antibiotic block of 
the channel.  Changes in hERG1A function (block) will alter IKr current.  If there is 
modification to a major repolarizing current of the cardiac AP, then the AP could 
be compromised.  The changing blocking characteristics of antibiotics on 
hERG1A with alterations in N-glycans could become relevant in individuals with 
pathologic changes in glycosylation.  One example to illustrate the possible 
impact of alterations in N-glycans is Chagas’ disease.  A patient afflicted with 
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Chagas’ disease typically presents with less sialylated cardiomyocytes meaning 
a potential for a shortened QT interval.  Given the data presented here, we might 
predict that if a Chagas’ patient is given Penicillin G, there may be a greater 
likelihood of drug block on hERG1A.  This increase in block could lead to an 
extension of the AP and may result in an adverse cardiac event.  However, since 
the Chagas’ patient may already have a short AP, then the Penicillin G might be 
used therapeutically to correct the affliction instead of causing one.  Our data 
show that sialic acid impact cardiac function differently when investigating on 
potassium channel’s function and drug block. 
 
Multiple diseases affect glycosylation states in the body and are linked to 
cardiovascular dysfunction.  Understanding the probable role of N-glycosylation 
on drug block will lead to safer drugs being put on the market. 
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CHAPTER 6 
FINAL DISCUSSION 
Cardiac action potential waveforms are produced by the gating of multiple ion 
channels.  A change in ion channel function can lead to arrhythmias, torsades de 
pointes, cardiac disease, and sudden cardiac death.  HERG1A, one of these ion 
channels, is partially responsible for the repolarization of the AP.  Dysfunction of 
hERG1A can result in multiple cardiac maladies and is the source of hundreds of 
types of cardiac arrhythmias.  Inherited, acquired, and drug induced arrhythmias 
can all occur with alterations in hERG1A. 
 
Physiologic and pathologic consequences 
The impact of N-glycan dependent hERG1A activity on AP waveform is unique 
among voltage-gated K+ channels  
Here we show a depolarizing shift in hERG1A voltage-dependent gating 
parameters with conditions of reduced glycosylation.  We believe that sialic acid 
play a large role in the micro environment surface charge surrounding many ion 
channels.  This surface charge directly affects normal function of the channels.  
This molecular mechanism is consistent with some previous studies of Kv1 and 
Kv4 channel isoforms (although not all), with conclusions made that reduced 
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sialylation of the affected Kv1 and Kv4 isoforms limits Kv channel activity during 
the AP (loss of function)65,87,93-95.  The negative sialic acids likely impact the shift 
in voltage-dependent gating through electrostatic mechanisms.  In fact, for 
several of these isoforms, only channel activation was affected by glycosylation.  
For Kv1.2 channel inactivation was enhanced by decreased glycosylation.  Both 
of these mechanisms would lead to a further loss of channel activity during the 
AP with reduced glycosylation71,72.  Here we show that a less sialylated hERG1A 
channel will be more active during the AP than a more heavily sialylated 
hERG1A channel (see Figure 15).  This gain of function with reduced 
glycosylation, primarily sialylation, is unique among Kv channel isoforms.   
 
Regulated changes in glycosylation could lead to modulated hERG1A activity 
Changes in N-linked sugar types and levels, particularly sialic acids, alter 
hERG1A function.  Previously, we showed that the glycogenes whose products 
are responsible for the addition and removal of glycans, are significantly 
differentially expressed in the atria versus ventricles and during development of 
each cardiac chamber66.  Further, our data suggested that cardiomyocyte N-
glycan structures are remodeled across the developing ventricle, particularly at 
the level of complex N-glycans.  We also showed that the major voltage-gated 
cardiac Na+ channel, Nav1.5, is less sialylated in the neonatal ventricle than in 
the adult ventricle, consistent with the regulated changes in cardiac ion channel 
sialylation93.  If hERG1A sialylation is similarly regulated throughout ventricle 
104 
 
development, then, given our data shown here, we would predict that the more 
sialylated adult hERG1A would be “less active” than the neonatal hERG1A  
during the ventricular AP, leading to an increased AP duration in the adult, as 
reported previously123,124. 
 
Aberrant changes in glycosylation could lead to hERG1A dysfunction 
It is well accepted that alterations in IKr often lead to aberrant cardiac AP 
repolarization and arrhythmias.  Currently, there are more than twenty-six known 
forms of Congenital Disorders of Glycosylation (CDG) with a prevalence of 1 in 
5000 births75-78.  Of these, most affect N-linked glycosylation.  CDG are genetic 
disorders that onset because of missing or mutant glycogenes, primarily 
glycosyltransferases.  The mutant/missing glycogene results in proteins and 
lipids with relatively modest reductions in glycosylation levels.  The minimally 
reduced levels of glycosylation grossly affect multiple systems including the 
cardiovascular system, with many CDG patients presenting cardiomyopathy 
and/or arrhythmias75-77.  If hERG1A channels of CDG patients are less sialylated, 
then one would predict decreased ventricular AP duration for those patients. 
 
Chagas’ disease (Trypanasoma cruzi – T. cruzi infection) is a human parasite 
disease that has no vaccine and no known cure and afflicts ~18 million people 
wordlwide80,82,83.  The mortality rate is ~30%, with nearly all terminal patients 
experiencing heart failure preceded by ventricular tachycardia81.  T. cruzi 
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releases a neuraminidase that cleaves sialic acids from the host tissue, which is 
typically the heart.  A recent study measured mouse ECG as a function of time 
post-infection using two strains of T. cruzi to infect.  The data indicated that ~60% 
of infected mice (compared to ~5% of control) showed some conduction 
abnormality125.  If hERG1A is less sialylated in chagasic patients, then one would 
predict increased hERG1A activity during the AP, and a decrease in AP duration 
that could contribute to the ventricular arrhythmias experienced by many of these 
patients.  Taken as a whole, alterations in N-glycosylation will alter gating and 
kinetics of hERG1A.  This, in turn, may lead to alterations in the AP and 
potentially adverse cardiac events.  Recognizing that small changes to N-glycans 
can have a large impact on the cardiac AP will facilitate understanding of many 
cardiac diseases. 
 
HERG1A antibiotic block is reduced with N-glycans 
Here, we showed that N-glycans are protective for hERG1A against antibiotic 
block.  SMX, Erythromycin, and Penicillin G block were each greater with 
reduced N-glycosylation, and block by each antibiotic was uniquely affected by 
N-glycans.  The data suggest that the negatively charged sialic acids seemed to 
alter block by SMX more than Erythromycin suggesting that the sugars affect the 
surface charge, and thereby alter the mechanism that SMX blocks the channel.  
However, Erythromycin does not seem to be affected by surface charge changes 
and its mechanism of block could be altered by sugars in a voltage dependent 
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manner whereby the membrane potential is altered by the absence of sialic acid 
on the extracellular surface causing an interior change to the binding site for 
Erythromycin.  Penicillin G was affected by both sialic acid and complex N-
glycosylation suggesting that its mechanism of block may be through surface 
charge effects, perhaps similarly to the effects of sialic acids on SMX block. 
 
Antibiotic block may happen through multiple pathways 
As discussed, one common theme of this report is that while N-glycans limit 
hERG1A function, they also serve to protect hERG1A from antibiotic block.  The 
N-glycans may protect against antibiotic block of hERG1A through several 
mechanisms.  First, the findings from chapter 3 predict that N-glycans alter the 
percentage of channels in a given state at a membrane potential and therefore 
there should be a change in the percentage of block at a given voltage.  That is, 
we would predict that the rightward shift in voltage-dependent activation that 
occurs with reduced glycosylation should cause a reduction in the percent block 
at a membrane potential given that block occurs in a state other than closed.  
However, this cannot be solely responsible for the variation in block with N-
glycans reported here.  In fact, because the data reported in chapter 5 are a ratio 
of block comparing the current with drug to current without drug, the N-glycan 
dependent modulation of gating on hERG1A is not measured.  In addition, the 
overall block would measure the ability of the drug to block all available channels 
because the percent block is determined as a change in maximal conductance.   
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Therefore, the data suggest an additional N-glycan effect on antibiotic block 
beyond altering the state dependence of the channel at a given voltage. 
 
A second possible mechanism by which N-glycans protect against antibiotic 
block may involve structural changes in how hERG1A sits in the membrane or its 
conformational state.  If N-glycans alter how the channel is inserted into or how it 
resides in the plasma membrane, then the affinity of a drug for its binding site 
might be affected by the change in structure or conformation.  Perhaps, even 
access of the drug to its site of block may be altered.  This could explain why 
hERG1A expressed in Lec1 cells has an increase in block by Erythromycin.  This 
potential conformational change to the channel may alter the binding site of 
Erythromycin giving the drug better access. 
 
A third possible mechanism involves a more direct effect in which N-glycans form 
a “shield” that limits drug interaction with the channel, almost like an umbrella 
keeping the drug from its site of action.  This shield could form a structural 
hindrance or, perhaps as suggested by the Lec2 studies on SMX (and perhaps 
Penicillin G), a charge effect.  Altering the surface charge surrounding the 
channel could directly affect the affinity of a drug for hERG1A.  Further studies 
need to be done to elucidate how N-glycans protect hERG1A from antibiotic 
block. 
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Future studies 
The data show that N-glycosylation alters gating and kinetics of hERG1A such 
that hERG1A function is limited by N-glycans.  Also, the data demonstrate that N-
glycans can protect hERG1A against antibiotic channel block.  Both findings are 
novel, potentially significant and likely occur through distinct mechanisms.  
However, they represent only a start to our understanding of the full extent that 
N-glycans impact hERG1A.  Future questions to be addressed include, 1) 
identifying how changes in block at small depolarizations (-40 to -10 mV range) 
may affect the cardiac AP.  Our findings indicate those voltages are relevant 
during Phase III where hERG1A is most active in the AP.  2)  determining the 
mechanisms by which N-glycans affect block by antibiotics, focusing on hERG1A 
block from either inside or outside of the cell and how N-glycans can alter both 
mechanisms.  Our data initially suggest that surface charge may play a role in 
altering drug block of hERG1A when the drug blocks from the outside, and 
complex N-glycans may modulate drug block from inside the pore region in a 
structural manner.  3) expand computer simulation of the human ventricle to 
include the effects of N-glycans on hERG1A function and block. 
 
Summary 
The hERG1A channel is essential to normal heart rhythm as hERG1A activity 
underlies IKr.  IKr is responsible for portions of phase II and phase III 
repolarization of the cardiac AP.  The data shown here indicate that hERG1A 
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activity is limited by N-glycans attached to the channel, with channel sialic acids 
responsible for most of the effect.  This will effectively extend the ventricular AP.  
As channel sialylation levels are altered, either physiologically or 
pathophysiologically, hERG1A activity and AP repolarization will be modulated.  
Physiological increases in channel sialylation would serve to further extend the 
AP, while physiological and pathological reductions in channel sialylation would 
lead to increased hERG1A activity and reduced AP durations. Either pathway 
could increase susceptibility to ventricular arrhythmia.  Thus, we have described 
a novel mechanism by which hERG1A activity can be modulated by regulated 
and aberrant changes in glycosylation, particularly sialylation.  Such modulation 
of hERG1A activity would affect the rate at which ventricular myocytes repolarize 
during the AP and potentially increase susceptibility to ventricular arrhythmias. 
 
Additionally, our findings show that N-glycans protect against antibiotic block of 
hERG1A, likely through mechanisms distinct from the impact of sialic acids on 
channel gating.  HERG1A can be blocked by a drug from outside of inside the 
cell.  These mechanisms could be through surface charge, conformational 
changes, and voltage dependent effects.  Total block by each antibiotic was 
affected differently by N-glycosylation.  Additionally, voltage dependent antibiotic 
block of hERG1A was modified by either sialic acids or complex N-glycans.  
Acquired Long QT syndrome can affect anyone, even someone who has no 
history of cardiac problems.  Understanding how glycosylation is modulated in 
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the heart, and how changes in glycosylation affect ion channel function may lead 
to development of better anti-arrhythmic drugs with fewer side effects (such as 
pro-arrhythmic behavior), prescribing the “right” medication, and even potentially 
reversing an adverse cardiac event. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
111 
 
 
 
 
 
 
 
CHAPTER 7 
 
REFERENCES 
 
 (1)  ten Tusscher KH, Noble D, Noble PJ, Panfilov AV. A model for human 
ventricular tissue. Am J Physiol Heart Circ Physiol. 2004;286:H1573-
H1589. 
 (2)  Armoundas AA, Wu R, Juang G, Marban E, Tomaselli GF. Electrical and 
structural remodeling of the failing ventricle. Pharmacol Ther. 
2001;92:213-230. 
 (3)  Nerbonne JM, Kass RS. Molecular Physiology of Cardiac Repolarization. 
Physiol Rev. 2005;85:1205-1253. 
 (4)  Olshansky B, Delmar M, Tomaselli GF. The year in arrhythmias-2009 
part II. Heart Rhythm. 2010;7:538-548. 
 (5)  Rosamond W, Flegal K, Furie K et al. Heart disease and stroke 
statistics--2008 update: a report from the American Heart Association 
Statistics Committee and Stroke Statistics Subcommittee. Circulation. 
2008;117:e25-146. 
 (6)  Tomaselli GF, Marban E. Electrophysiological remodeling in hypertrophy 
and heart failure. Cardiovasc Res. 1999;42:270-283. 
 (7)  Keating MT, Sanguinetti MC. Molecular and Cellular Mechanisms of 
Cardiac Arrhythmias. Cell. 2001;104:569-580. 
 (8)  Zhou Z, Gong Q, Epstein ML, January CT. HERG Channel Dysfunction 
in Human Long QT Syndrome. INTRACELLULAR TRANSPORT AND 
FUNCTIONAL DEFECTS. J Biol Chem. 1998;273:21061-21066. 
112 
 
 (9)  Wilde AAM, Postema PG, Di Diego JM et al. The pathophysiological 
mechanism underlying Brugada syndrome: Depolarization versus 
repolarization. Journal of Molecular and Cellular Cardiology. 
2010;49:543-553. 
 (10)  Westenskow P, Splawski I, Timothy KW, Keating MT, Sanguinetti MC. 
Compound mutations: a common cause of severe long-QT syndrome. 
Circulation. 2004;109:1834-1841. 
 (11)  Towbin JA, Wang Z, Li H. Genotype and Severity of Long QT Syndrome. 
Drug Metab Dispos. 2001;29:574-579. 
 (12)  Tomaselli GF. Cardiac I(to), KCNE2, and Brugada syndrome: 
promiscuous subunit interactions, or what happens in HEK cells stays in 
HEK cells? Heart Rhythm. 2010;7:206-207. 
 (13)  Teng GQ, Lees-Miller JP, Duan Y, Li BT, Li P, Duff HJ. [K+]o-dependent 
change in conformation of the HERG1 long QT mutation N629D channel 
results in partial reversal of the in vitro disease phenotype. 
Cardiovascular Research. 2003;57:642-650. 
 (14)  Splawski I, Shen J, Timothy KW et al. Spectrum of Mutations in Long-QT 
Syndrome Genes : KVLQT1, HERG, SCN5A, KCNE1, and KCNE2. 
Circulation. 2000;102:1178-1185. 
 (15)  Roden DM, Lazzara R, Rosen M, Schwartz PJ, Towbin J, Vincent GM. 
Multiple Mechanisms in the Long-QT Syndrome: Current Knowledge, 
Gaps, and Future Directions. Circulation. 1996;94:1996-2012. 
 (16)  Roden DM, Balser JR. A plethora of mechanisms in the HERG-related 
long QT syndrome: Genetics meets electrophysiology. Cardiovascular 
Research. 1999;44:242-246. 
 (17)  Trudeau MC, Warmke JW, Ganetzky B, Robertson GA. HERG, a human 
inward rectifier in the voltage-gated potassium channel family. Science. 
1995;269:92-95. 
 
113 
 
 (18)  Sanguinetti MC, Jiang C, Curran ME, Keating MT. A Mechanistic Link 
between an Inherited and an Acquired Cardiac Arrhythmia: HERG 
encodes the IKr Potassium Channel. Cell. 1995;81:299-307. 
 (19)  Curran ME, Splawski I, Timothy KW, Vincent GM, Green ED, Keating 
MT. A Molecular Basis for Cardiac Arrhythmia: HERG Mutations Cause 
Long QT Syndrome. Cell. 1995;80:795-803. 
 (20)  Sanguinetti MC, Curran ME, Spector PS, Keating MT. Spectrum of 
HERG K+-channel dysfunction in an inherited cardiac arrhythmia. PNAS. 
1996;93:2208-2212. 
 (21)  Sanguinetti MC, Tristani-Firouzi M. hERG potassium channels and 
cardiac arrhythmia. Nature. 2006;440:463-469. 
 (22)  Huang FD, Chen J, Lin M, Keating MT, Sanguinetti MC. Long-QT 
syndrome-associated missense mutations in the pore helix of the HERG 
potassium channel. Circulation. 2001;104:1071-1075. 
 (23)  Chen J, Zou A, Splawski I, Keating MT, Sanguinetti MC. Long QT 
syndrome-associated mutations in the Per-Arnt-Sim (PAS) domain of 
HERG potassium channels accelerate channel deactivation. J Biol 
Chem. 1999;274:10113-10118. 
 (24)  Abbott GW, Sesti F, Splawski I et al. MiRP1 Forms IKr Potassium 
Channels with HERG and Is Associated with Cardiac Arrhythmia. Cell. 
1999;97:175-187. 
 (25)  Mazhari R, Greenstein JL, Winslow RL, Marban E, Nuss HB. Molecular 
Interactions Between Two Long-QT Syndrome Gene Products, HERG 
and KCNE2, Rationalized by In Vitro and In Silico Analysis. Circ Res. 
2001;89:33-38. 
 (26)  Ravens U, Cerbai E. Role of potassium currents in cardiac arrhythmias. 
Europace. 2008;10:1133-1137. 
 
114 
 
 (27)  Cordeiro JM, Brugada R, Wu YS, Hong K, Dumaine R. Modulation of IKr 
inactivation by mutation N588K in KCNH2: A link to arrhythmogenesis in 
short QT syndrome. Cardiovascular Research. 2005;67:498-509. 
 (28)  Sanguinetti MC, Jiang C, Curran ME, Keating MT. A mechanistic link 
between an inherited and an acquired cardiac arrhythmia: HERG 
encodes the IKr potassium channel. Cell. 1995;81:299-307. 
 (29)  Sanguinetti MC, Curran ME, Spector PS, Keating MT. Spectrum of 
HERG K+-channel dysfunction in an inherited cardiac arrhythmia. Proc 
Natl Acad Sci U S A. 1996;93:2208-2212. 
 (30)  Sanguinetti MC, Zou A. Molecular physiology of cardiac delayed rectifier 
K+ channels. Heart Vessels. 1997;Suppl 12:170-172. 
 (31)  Sanguinetti MC, Tristani-Firouzi M. hERG potassium channels and 
cardiac arrhythmia. Nature. 2006;440:463-469. 
 (32)  Heginbotham L, Lu Z, Abramson T, MacKinnon R. Mutations in the K+ 
channel signature sequence. Biophysical Journal. 1994;66:1061-1067. 
 (33)  Shepard PD, Trudeau MC. Emerging roles for ether-a-go-go-related 
gene potassium channels in the brain. J Physiol. 2008;586:4785-4786. 
 (34)  Anson BD, Ackerman MJ, Tester DJ et al. Molecular and functional 
characterization of common polymorphisms in HERG (KCNH2) 
potassium channels. Am J Physiol Heart Circ Physiol. 2004;286:H2434-
H2441. 
 (35)  Antzelevitch P, Sun MPZ-Q, Zhang MD, Yan MPG-X. Cellular and Ionic 
Mechanisms Underlying Erythromycin-Induced Long QT Intervals and 
Torsade de Pointes. Journal of the American College of Cardiology. 
1996;28:1836-1848. 
 (36)  Bennett PB, Yazawa K, Makita N, George AL, Jr. Molecular mechanism 
for an inherited cardiac arrhythmia. Nature. 1995;376:683-685. 
115 
 
 (37)  Bennett PB. Long QT syndrome: biophysical and pharmacologic 
mechanisms in LQT3. J Cardiovasc Electrophysiol. 2000;11:819-822. 
 (38)  Brundel BJ, van G, I, Henning RH et al. Alterations in potassium channel 
gene expression in atria of patients with persistent and paroxysmal atrial 
fibrillation: differential regulation of protein and mRNA levels for K+ 
channels. J Am Coll Cardiol. 2001;37:926-932. 
 (39)  Brundel BJ, Henning RH, Kampinga HH, van G, I, Crijns HJ. Molecular 
mechanisms of remodeling in human atrial fibrillation. Cardiovasc Res. 
2002;54:315-324. 
 (40)  Compton SJ, Lux RL, Ramsey MR et al. Genetically defined therapy of 
inherited long-QT syndrome. Correction of abnormal repolarization by 
potassium. Circulation. 1996;94:1018-1022. 
 (41)  Daleau P, Lessard E, Groleau MF, Turgeon J. Erythromycin Blocks the 
Rapid Component of the Delayed Rectifier Potassium Current and 
Lengthens Repolarization of Guinea Pig Ventricular Myocytes. 
Circulation. 1995;91:3010-3016. 
 (42)  Friederich P, Solth A, Schillemeit S, Isbrandt D. Local anaesthetic 
sensitivities of cloned HERG channels from human heart: comparison 
with HERG/MiRP1 and HERG/MiRP1T8A. Br J Anaesth. 2004;92:93-
101. 
 (43)  Ganapathi SB, Kester M, Elmslie KS. State-dependent block of HERG 
potassium channels by R-roscovitine: implications for cancer therapy. 
Am J Physiol Cell Physiol. 2009;296:C701-C710. 
 (44)  Gong Q, Jones MA, Zhou Z. Mechanisms of Pharmacological Rescue of 
Trafficking-defective hERG Mutant Channels in Human Long QT 
Syndrome. J Biol Chem. 2006;281:4069-4074. 
 (45)  Guo J, Zhan S, Lees-Miller JP, Teng G, Duff HJ. Exaggerated block of 
hERG (KCNH2) and prolongation of action potential duration by 
erythromycin at temperatures between 37[degree sign]C and 42[degree 
sign]C. Heart Rhythm. 2005;2:860-866. 
116 
 
 (46)  Haverkamp W, Breithardt G, Camm AJ et al. The potential for QT 
prolongation and proarrhythmia by non-antiarrhythmic drugs: clinical and 
regulatory implications. Report on a Policy Conference of the European 
Society of Cardiology. Eur Heart J. 2000;21:1216-1231. 
 (47)  Herzberg IM, Trudeau MC, Robertson GA. Transfer of rapid inactivation 
and sensitivity to the class III antiarrhythmic drug E-4031 from HERG to 
M-eag channels. J Physiol (Lond). 1998;511:3-14. 
 (48)  Kamiya K, Niwa R, Mitcheson JS, Sanguinetti MC. Molecular 
determinants of HERG channel block. Mol Pharmacol. 2006;69:1709-
1716. 
 (49)  Lee MB KL, Jim MB MH, Tang MB SC, Tai MB YT. QT Prolongation and 
Torsades de Pointes Associated with Clarithromycin. The American 
Journal of Medicine. 1998;104:395-396. 
 (50)  Mitcheson JS, Chen J, Lin M, Culberson C, Sanguinetti MC. A structural 
basis for drug-induced long QT syndrome. Proc Natl Acad Sci U S A. 
2000;97:12329-12333. 
 (51)  Olshansky B, Delmar M, Tomaselli GF. The year in arrhythmias--2009: 
part I. Heart Rhythm. 2010;7:417-426. 
 (52)  Phillip J.Stansfeld, Peter Gedeck, Martin Gosling, Brian Cox, John 
S.Mitcheson, Michael J.Sutcliffe. Drug block of the hERG potassium 
channel: Insight from modeling. 2007:568-80. 
 (53)  Sanchez-Chapula JA, Navarro-Polanco RA, Culberson C, Chen J, 
Sanguinetti MC. Molecular determinants of voltage-dependent human 
ether-a-go-go related gene (HERG) K+ channel block. J Biol Chem. 
2002;277:23587-23595. 
 (54)  Sanguinetti MC, Bennett PB. Antiarrhythmic drug target choices and 
screening. Circ Res. 2003;93:491-499. 
 (55)  Sanguinetti MC, Chen J, Fernandez D, Kamiya K, Mitcheson J, 
Sanchez-Chapula JA. Physicochemical basis for binding and voltage-
117 
 
dependent block of hERG channels by structurally diverse drugs. 
Novartis Found Symp. 2005;266:159-166. 
 (56)  Spector PS, Curran ME, Keating MT, Sanguinetti MC. Class III 
antiarrhythmic drugs block HERG, a human cardiac delayed rectifier K+ 
channel. Open-channel block by methanesulfonanilides. Circ Res. 
1996;78:499-503. 
 (57)  Yoshida K, Niwa T. Quantitative Structure-Activity Relationship Studies 
on Inhibition of HERG Potassium Channels. J Chem Inf Model. 
2006;46:1371-1378. 
 (58)  Znnkler BJ. Human ether-a-go-go-related (HERG) gene and ATP-
sensitive potassium channels as targets for adverse drug effects. 
Pharmacology & Therapeutics. 2006;112:12-37. 
 (59)  Petrecca K, Atanasiu R, Akhavan A, Shrier A. N-linked glycosylation 
sites determine HERG channel surface membrane expression. J Physiol 
(Lond). 1999;515:41-48. 
 (60)  Gong Q, Anderson CL, January CT, Zhou Z. Role of glycosylation in cell 
surface expression and stability of HERG potassium channels. Am J 
Physiol Heart Circ Physiol. 2002;283:H77-H84. 
 (61)  Bennett E, Urcan MS, Tinkle SS, Koszowski AG, Levinson SR. 
Contribution of sialic acid to the voltage dependence of sodium channel 
gating. A possible electrostatic mechanism. J Gen Physiol. 
1997;109:327-343. 
 (62)  Bennett ES. Effects of channel cytoplasmic regions on the activation 
mechanisms of cardiac versus skeletal muscle Na(+) channels. Biophys 
J. 1999;77:2999-3009. 
 (63)  Bennett ES. Channel cytoplasmic loops alter voltage-dependent sodium 
channel activation in an isoform-specific manner. J Physiol. 
2001;535:371-381. 
 
118 
 
 (64)  Bennett ES. Isoform-specific effects of sialic acid on voltage-dependent 
Na+ channel gating: functional sialic acids are localized to the S5-S6 
loop of domain I. J Physiol. 2002;538:675-690. 
 (65)  Johnson D, Bennett ES. Isoform-specific Effects of the beta2 Subunit on 
Voltage-gated Sodium Channel Gating. J Biol Chem. 2006;281:25875-
25881. 
 (66)  Montpetit ML, Stocker PJ, Schwetz TA et al. Regulated and aberrant 
glycosylation modulate cardiac electrical signaling. Proc Natl Acad Sci U 
S A. 2009;106:16517-16522. 
 (67)  Schwetz TA, Norring SA, Bennett ES. N-glycans modulate K(v)1.5 
gating but have no effect on K(v)1.4 gating. Biochim Biophys Acta. 
2010;1798:367-375. 
 (68)  Ufret-Vincenty CA, Baro DJ, Lederer WJ, Rockman HA, Quinones LE, 
Santana LF. Role of sodium channel deglycosylation in the genesis of 
cardiac arrhythmias in heart failure. J Biol Chem. 2001;276:28197-
28203. 
 (69)  Ufret-Vincenty CA, Baro DJ, Santana LF. Differential contribution of 
sialic acid to the function of repolarizing K(+) currents in ventricular 
myocytes. Am J Physiol Cell Physiol. 2001;281:C464-C474. 
 (70)  Watanabe I, Zhu J, Recio-Pinto E, Thornhill WB. Glycosylation Affects 
the Protein Stability and Cell Surface Expression of Kv1.4 but Not Kv1.1 
Potassium Channels. J Biol Chem. 2004;279:8879-8885. 
 (71)  Watanabe I, Zhu J, Sutachan JJ, Gottschalk A, Recio-Pinto E, Thornhill 
WB. The glycosylation state of Kv1.2 potassium channels affects 
trafficking, gating, and simulated action potentials. Brain Research. 
2007;1144:1-18. 
 (72)  Zhu J, Recio-Pinto E, Hartwig T, Sellers W, Yan J, Thornhill WB. The 
Kv1.2 potassium channel: The position of an N-glycan on the 
extracellular linkers affects its protein expression and function. Brain 
Research. 2009;1251:16-29. 
119 
 
 (73)  Snider MD, Rogers OC. Intracellular movement of cell surface receptors 
after endocytosis: resialylation of asialo-transferrin receptor in human 
erythroleukemia cells. J Cell Biol. 1985;100:826-834. 
 (74)  Snider MD, Rogers OC. Membrane traffic in animal cells: cellular 
glycoproteins return to the site of Golgi mannosidase I. J Cell Biol. 
1986;103:265-275. 
 (75)  Jaeken J. Komrower Lecture. Congenital disorders of glycosylation 
(CDG): it's all in it! J Inherit Metab Dis. 2003;26:99-118. 
 (76)  Jaeken J, Carchon H. Congenital disorders of glycosylation: a booming 
chapter of pediatrics. Curr Opin Pediatr. 2004;16:434-439. 
 (77)  Jaeken J. Congenital disorders of glycosylation (CDG): update and new 
developments. J Inherit Metab Dis. 2004;27:423-426. 
 (78)  Marquardt T, Denecke J. Congenital disorders of glycosylation: review of 
their molecular bases, clinical presentations and specific therapies. Eur J 
Pediatr. 2003;162:359-379. 
 (79)  Bern C, Montgomery SP, Herwaldt BL et al. Evaluation and Treatment of 
Chagas Disease in the United States: A Systematic Review. JAMA. 
2007;298:2171-2181. 
 (80)  Bestetti RB, Muccillo G. Clinical course of Chagas' heart disease: a 
comparison with dilated cardiomyopathy. International Journal of 
Cardiology. 1997;60:187-193. 
 (81)  Biolo A, Ribeiro AL, Clausell N. Chagas Cardiomyopathy--Where Do We 
Stand After a Hundred Years? Progress in Cardiovascular Diseases. 
2001;52:300-316. 
 (82)  Tribulatti MV, Mucci J, Van Rooijen N, Leguizamon MS, Campetella O. 
The trans-Sialidase from Trypanosoma cruzi Induces Thrombocytopenia 
during Acute Chagas' Disease by Reducing the Platelet Sialic Acid 
Contents. Infect Immun. 2005;73:201-207. 
120 
 
 (83)  Libby P, Alroy J, Pereira ME. A neuraminidase from Trypanosoma cruzi 
removes sialic acid from the surface of mammalian myocardial and 
endothelial cells. Journal of Clinical Investigation. 1986;77:127-135. 
 (84)  Johnson D, Bennett ES. Gating of the shaker potassium channel is 
modulated differentially by N-glycosylation and sialic acids. Pflugers 
Arch. 2008;456:393-405. 
 (85)  Stanley P, Caillibot V, Siminovitch L. Selection and Characterization of 
Eight Phenotypically Distinct Lines of Lectin-resistant Chinese Hamster 
Ovary Cell. Cell. 1975;6:121-128. 
 (86)  Bennett ES. Channel activation voltage alone is directly altered in an 
isoform-specific manner by Na(v1.4) and Na(v1.5) cytoplasmic linkers. J 
Membr Biol. 2004;197:155-168. 
 (87)  Johnson D, Montpetit ML, Stocker PJ, Bennett ES. The sialic acid 
component of the beta1 subunit modulates voltage-gated sodium 
channel function. J Biol Chem. 2004;279:44303-44310. 
 (88)  Warmke JW, Ganetzky B. A family of potassium channel genes related 
to eag in Drosophila and mammals. Proceedings of the National 
Academy of Sciences of the United States of America. 1994;91:3438-
3442. 
 (89)  Cordeiro JM, Brugada R, Wu YS, Hong K, Dumaine R. Modulation of IKr 
inactivation by mutation N588K in KCNH2: A link to arrhythmogenesis in 
short QT syndrome. Cardiovascular Research. 2005;67:498-509. 
 (90)  Spector PS, Curran ME, Zou A, Keating MT, Sanguinetti MC. Fast 
inactivation causes rectification of the IKr channel. J Gen Physiol. 
1996;107:611-619. 
 (91)  Sparks S. Inherited Disorders of Glycosylation. Molecular Genetics and 
Metabolism. 2006;87:1-7. 
 
121 
 
 (92)  Santacruz-Toloza L, Huang Y, John SA, Papazian DM. Glycosylation of 
shaker potassium channel protein in insect cell culture and in Xenopus 
oocytes. Biochemistry. 1994;33:5607-5613. 
 (93)  Stocker PJ, Bennett ES. Differential Sialylation Modulates Voltage-gated 
Na+ Channel Gating throughout the Developing Myocardium. J Gen 
Physiol. 2006;127:253-265. 
 (94)  Bennett E, Urcan MS, Tinkle SS, Koszowski AG, Levinson SR. 
Contribution of Sialic Acid to the Voltage Dependence of Sodium 
Channel Gating . A Possible Electrostatic Mechanism. J Gen Physiol. 
1997;109:327-343. 
 (95)  Bennett ES. Isoform-specific effects of sialic acid on voltage-dependent 
Na+ channel gating: functional sialic acids are localized to the S5-S6 
loop of domain I. J Physiol (Lond). 2002;538:675-690. 
 (96)  Thornhill WB, Wu MB, Jiang X, Wu X, Morgan PT, Margiotta JF. 
Expression of Kv1.1 Delayed Rectifier Potassium Channels in Lec 
Mutant Chinese Hamster Ovary Cell Lines Reveals a Role for Sialidation 
in Channel Function. J Biol Chem. 1996;271:19093-19098. 
 (97)  Schwetz TA, Norring SA, Bennett ES. N-glycans modulate Kv1.5 gating 
but have no effect on Kv1.4 gating. Biochimica et Biophysica Acta (BBA) 
- Biomembranes. 2010;1798:367-375. 
 (98)  Montpetit ML, Stocker PJ, Schwetz TA et al. Regulated and aberrant 
glycosylation modulate cardiac electrical signaling. PNAS. 2009. 
 (99)  Mehta D, Warwick G, Goldberg M. QT Prolongation after Ampicillin 
Anaphylaxis. British Heart Journal. 1986;55:308-310. 
 (100)  Hardman RM, Stansfeld PJ, Dalibalta S, Sutcliffe MJ, Mitcheson JS. 
Activation gating of hERG potassium channels: S6 glycines are not 
required as gating hinges. J Biol Chem. 2007;282:31972-31981. 
 
122 
 
 (101)  Stansfeld PJ, Gedeck P, Gosling M, Cox B, Mitcheson JS, Sutcliffe MJ. 
Drug block of the hERG potassium channel: insight from modeling. 
Proteins. 2007;68:568-580. 
 (102)  Norring SA, Schwetz TA, Bennett ES. Penicillin G Blocks hERG1A. 
Manuscript in preparation. 2010. 
 (103)  Belus A, White E. Effects of streptomycin sulphate on ICaL, IKr and IKs 
in guinea-pig ventricular myocytes. European Journal of Pharmacology. 
2002;445:171-178. 
 (104)  Fernandez D, Ghanta A, Kauffman GW, Sanguinetti MC. 
Physicochemical features of the HERG channel drug binding site. J Biol 
Chem. 2004;279:10120-10127. 
 (105)  Sanguinetti MC, Mitcheson JS. Predicting drug-hERG channel 
interactions that cause acquired long QT syndrome. Trends Pharmacol 
Sci. 2005;26:119-124. 
 (106)  De Bruin ML, van Staa TP, Belitser SV, Leufkens HG, Hoes AW. 
Predicting cardiac arrhythmias and sudden death in diabetic users of 
proarrhythmic drugs. Diabetes Care. 2005;28:440-442. 
 (107)  De Bruin ML, Pettersson M, Meyboom RH, Hoes AW, Leufkens HG. 
Anti-HERG activity and the risk of drug-induced arrhythmias and sudden 
death. Eur Heart J. 2005;26:590-597. 
 (108)  De Bruin ML, van Hemel NM, Leufkens HG, Hoes AW. Hospital 
discharge diagnoses of ventricular arrhythmias and cardiac arrest were 
useful for epidemiologic research. J Clin Epidemiol. 2005;58:1325-1329. 
 (109)  Sanchez-Chapula JA, Sanguinetti MC. Altered gating of HERG 
potassium channels by cobalt and lanthanum. Pflugers Arch. 
2000;440:264-274. 
 (110)  Sanguinetti MC, Mitcheson JS. Predicting drug-hERG channel 
interactions that cause acquired long QT syndrome. Trends in 
Pharmacological Sciences. 2005;26:119-124. 
123 
 
 (111)  Ho WK, Kim I, Lee CO, Youm JB, Lee SH, Earm YE. Blockade of HERG 
channels expressed in Xenopus laevis oocytes by external divalent 
cations. Biophys J. 1999;76:1959-1971. 
 (112)  Lin MC, Papazian DM. Differences between ion binding to eag and 
HERG voltage sensors contribute to differential regulation of activation 
and deactivation gating. Channels (Austin ). 2007;1:429-437. 
 (113)  Farid R, Day T, Friesner RA, Pearlstein RA. New insights about HERG 
blockade obtained from protein modeling, potential energy mapping, and 
docking studies. Bioorg Med Chem. 2006;14:3160-3173. 
 (114)  Perrin MJ, Subbiah RN, Vandenberg JI, Hill AP. Human ether-a-go-go 
related gene (hERG) K+ channels: function and dysfunction. Prog 
Biophys Mol Biol. 2008;98:137-148. 
 (115)  Mitcheson J, Perry M, Stansfeld P, Sanguinetti MC, Witchel H, Hancox 
J. Structural determinants for high-affinity block of hERG potassium 
channels. Novartis Found Symp. 2005;266:136-150. 
 (116)  Ficker E, Jarolimek W, Kiehn J, Baumann A, Brown AM. Molecular 
determinants of dofetilide block of HERG K+ channels. Circ Res. 
1998;82:386-395. 
 (117)  Abbott GW, Goldstein SAN. Potassium Channel Subunits: The MiRP 
Family. Mol Interv. 2001;1:95-107. 
 (118)  Milberg P, Eckardt L, Bruns HJ et al. Divergent Proarrhythmic Potential 
of Macrolide Antibiotics Despite Similar QT Prolongation: Fast Phase 3 
Repolarization Prevents Early Afterdepolarizations and Torsade de 
Pointes. J Pharmacol Exp Ther. 2002;303:218-225. 
 (119)  Park KH, Kwok SM, Sharon C, Baerga R, Sesti F. N-glycosylation-
dependent block is a novel mechanism for drug-induced cardiac 
arrhythmia. FASEB J. 2003;03-0577fje. 
 
124 
 
 (120)  Sanguinetti MC, Jurkiewicz NK. Two components of cardiac delayed 
rectifier K+ current. Differential sensitivity to block by class III 
antiarrhythmic agents. J Gen Physiol. 1990;96:195-215. 
 (121)  Sesti F, Abbott GW, Wei J et al. A common polymorphism associated 
with antibiotic-induced cardiac arrhythmia. PNAS. 2000;97:10613-10618. 
 (122)  Norring SA, Schwetz TA, Ednie AR, Bennett ES. N-Glycans Alter 
Antibiotic Block of hERG1A. Manuscript in preparation. 2010. 
 (123)  Krasemann T, Bente K, Burkhardtsmaier G. The corrected QT interval in 
24-áh  ECGs in neonates. Clinical Research in Cardiology. 
2010;99:309-314. 
 (124)  Taubel J, Naseem A, Harada T et al. Levofloxacin can be used 
effectively as a positive control in thorough QT/QTc studies in healthy 
volunteers. Br J Clin Pharmacol. 2010;69:391-400. 
 (125)  Bustamante JM, Rivarola HW, Fretes R, Paglini-Oliva PA. Weekly 
electrocardiographic pattern in mice infected with two different 
Trypanosoma cruzi strains. International Journal of Cardiology. 
2005;102:211-217. 
 
 
  
 
 
 
ABOUT THE AUTHOR 
 
Sarah Ann Norring was born December 6, 1978 in Skokie, Illinois.  She 
graduated from Mundelein High School in 1996.  Sarah enrolled at the University 
of Illinois, Urbana-Champaign in the Biology program in the College of Liberal 
Arts & Sciences where she made the Dean’s List multiple semesters.  In 2000, 
she graduated with a B.S. in Biology.  That year, Sarah started working for 
Pharmacia Corporation in the Medicinal Chemistry department for her first year 
out of undergraduate school.  She then moved to Salt Lake City, UT and began 
work with the Analytical Method Development team at Cephalon, Inc.  In 2005, 
Sarah joined the laboratory of Eric S. Bennett, Ph.D. at the University of South 
Florida.  She was awarded an AHA Pre-doctoral Fellowship while at USF.  She 
earned her M.S.M.S. and was accepted as a doctoral candidate in 2007.  Sarah 
was conferred with a Ph.D. in Medical Sciences from the University of South 
Florida, College of Medicine in 2010. 
